BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor.

To screen and evaluate protein biomarkers for the detection of gliomas (Astrocytoma grade I-IV) from healthy individuals and gliomas from brain benign tumors by using surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) coupled with an artificial neural network (ANN) algorithm.

SELDI-TOF-MS protein fingerprinting of serum from 105 brain tumor patients and healthy individuals, included 28 patients with glioma (Astrocytoma I-IV), 37 patients with brain benign tumor, and 40 age-matched healthy individuals.

Two thirds of the total samples of every compared pair as training set were used to set up discriminating patterns, and one third of total samples of every compared pair as test set were used to cross-validate; simultaneously, discriminate-cluster analysis derived SPSS 10.0 software was used to compare Astrocytoma grade I-II with grade III-IV ones.

An accuracy of 95.7%, sensitivity of 88.9%, specificity of 100%, positive predictive value of 90% and negative predictive value of 100% were obtained in a blinded test set comparing gliomas patients with healthy individuals; an accuracy of 86.4%, sensitivity of 88.9%, specificity of 84.6%, positive predictive value of 90% and negative predictive value of 85.7% were obtained when patient's gliomas was compared with benign brain tumor.

Total accuracy of 85.7%, accuracy of grade I-II Astrocytoma was 86.7%, accuracy of III-IV Astrocytoma was 84.6% were obtained when grade I-II Astrocytoma was compared with grade III-IV ones (discriminant analysis).

The high sensitivity and specificity achieved by the use of selected biomarkers showed great potential application for the discrimination of gliomas patients from healthy individuals and gliomas from brain benign tumors.

[MeSH-major] Astrocytoma / blood. Astrocytoma / diagnosis. Biomarkers, Tumor / blood. Brain Neoplasms / blood. Brain Neoplasms / diagnosis. Diagnosis, Computer-Assisted / methods. Neoplasm Proteins / blood. Peptide Mapping / methods

Genetic Alliance. consumer health - Glioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]

[Cites] Pain. 2003 Apr;102(3):251-6 [12670666.001]

[Cites] Curr Med Chem. 2003 May;10(10):831-43 [12678686.001]

[Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s [12743135.001]

[Cites] Lung Cancer. 2003 Jun;40(3):267-79 [12781425.001]

[Cites] Curr Pharm Biotechnol. 2004 Feb;5(1):45-67 [14965209.001]

[Cites] Curr Opin Biotechnol. 2004 Feb;15(1):24-30 [15102462.001]

[Cites] Electrophoresis. 2000 Apr;21(6):1164-77 [10786889.001]

[Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]

[Cites] Bioinformatics. 2002 Mar;18(3):395-404 [11934738.001]

[Cites] Clin Chem. 2002 Aug;48(8):1160-9 [12142368.001]

[Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]

[Cites] Clin Cancer Res. 2002 Aug;8(8):2541-52 [12171882.001]

(PMID = 15593384.001).

[ISSN] 1673-1581

[Journal-full-title] Journal of Zhejiang University. Science. B

[ISO-abbreviation] J Zhejiang Univ Sci B

[Language] eng

[Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Letter; Research Support, Non-U.S. Gov't; Validation Studies

[Publication-country] China

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins

[Other-IDs] NLM/ PMC1390751

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Efficacy of prognostic factors on survival in patients with low grade glioma.

AIM: In this report, we aim to determine the prognostic factors influencing the length of survival in patients with low-grade gliomas.

The diagnoses of the patients were histopathologically verified as low-grade glioma(LGG).

The medical records of the patients were reviewed for age, gender, tumor locations, extent of resection, and presence of seizure, the neurological status as defined by the Karnofsky Performance Scale (KPS) and radiotherapy treatment after surgery as possible prognostic factors.

Median survival time was 216+/-78.52 months for astrocytoma Grade I; 115+/-8.22 months for astrocytoma Grade II, and 242+/-76.36 months for oligodendroglioma.

[MeSH-minor] Adolescent. Adult. Aged. Aging. Astrocytoma / mortality. Astrocytoma / pathology. Astrocytoma / surgery. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Karnofsky Performance Status. Magnetic Resonance Imaging. Male. Middle Aged. Neurosurgical Procedures. Oligodendroglioma / mortality. Oligodendroglioma / pathology. Oligodendroglioma / surgery. Prognosis. Reoperation. Retrospective Studies. Seizures / etiology. Survival. Tomography, X-Ray Computed. Young Adult

Genetic Alliance. consumer health - Glioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19107679.001).

[ISSN] 1019-5149

[Journal-full-title] Turkish neurosurgery

[ISO-abbreviation] Turk Neurosurg

[Language] eng

[Publication-type] Journal Article

[Publication-country] Turkey

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The corresponding results were for astrocytoma grade III-IV OR = 1.7, 95 % CI = 1.3-2.3; OR = 1.5, 95 % CI = 1.2-1.9 and OR = 1.5, 95 % CI = 1.1-1.9, respectively.

Lower ORs were calculated for astrocytoma grade I-II.

OR increased with latency period, especially for astrocytoma grade III-IV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int J Oncol. 2006 Feb;28(2):509-18 [16391807.001]

[Cites] Arch Environ Health. 2004 Mar;59(3):132-7 [16121902.001]

[Cites] Environ Res. 2006 Feb;100(2):232-41 [16023098.001]

[Cites] Environ Health Perspect. 2003 Nov;111(14):1704-6 [14594618.001]

[Cites] Neuroepidemiology. 2005;25(3):120-8 [15956809.001]

[Cites] Eur J Cancer Prev. 2005 Jun;14(3):285-8 [15902000.001]

[Cites] Occup Environ Med. 2004 Aug;61(8):675-9 [15258273.001]

[Cites] Occup Environ Med. 2004 Jun;61(6):560-70, 487 [15150403.001]

[Cites] Int J Cancer. 2004 Apr 10;109(3):425-9 [14961582.001]

[Cites] Int Arch Occup Environ Health. 2006 Sep;79(8):630-9 [16541280.001]

[Cites] Electromagn Biol Med. 2006;25(1):45-51 [16595333.001]

[Cites] Int J Oncol. 1999 Jul;15(1):113-6 [10375602.001]

[Cites] Eur J Cancer Prev. 2001 Dec;10(6):523-9 [11916351.001]

[Cites] Eur J Cancer Prev. 2002 Aug;11(4):377-86 [12195165.001]

[Cites] Int J Oncol. 2003 Feb;22(2):399-407 [12527940.001]

[Cites] Neuroepidemiology. 2003 Mar-Apr;22(2):124-9 [12629278.001]

[Cites] Int Arch Occup Environ Health. 2005 Sep;78(8):625-32 [16001209.001]

[Cites] Occup Environ Med. 2005 Jun;62(6):390-4 [15901886.001]

(PMID = 17034627.001).

[ISSN] 1477-7819

[Journal-full-title] World journal of surgical oncology

[ISO-abbreviation] World J Surg Oncol

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Other-IDs] NLM/ PMC1621063

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Spontaneous malignant transformation of a supratentorial pilocytic astrocytoma.

Pilocytic astrocytoma (PA) is a circumscribed neoplasia considered as a grade I astrocytoma by the World Health Organization.

[MeSH-major] Astrocytoma / pathology. Cell Transformation, Neoplastic / pathology. Supratentorial Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20571729.001).

[ISSN] 1130-1473

[Journal-full-title] Neurocirugía (Asturias, Spain)

[ISO-abbreviation] Neurocirugia (Astur)

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Spain

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The aim is to define the histological type of glioma (astrocytic, oligodendrocytic or mixed) and the grade in order to classify the patients and give them an accurate treatment.

According to the WHO classification, infiltrative gliomas encompass astrocytic gliomas (diffuse astrocytomas grade II, anaplastic astrocytomas grade III and glioblastomas grade IV), oligodendroglial tumours (oligodendrogliomas grade II, anaplastic oligodendrogliomas grade III) and mixed gliomas (oligoastrocytomas grade II and anaplastic oligoastrocytomas grade III).

Circumscribed gliomas mainly corresponds to pilocytic astrocytomas (grade I).

Three distinct tumour growth patterns may be seen in gliomas, type I: tumor tissue only, type II: tumour tissue and isolated tumor cells permeating the brain parenchyma (ITC) and type III: ITCs only and no tumor tissue.

According to the Sainte Anne classification, gliomas are divided into astrocytic gliomas (pilocytic astrocytomas, structure type I, glioblastomas structure type II) and oligodendrogliomas and mixed oligoastrocytomas (grade A: lack of contrast enhancement and lack of endothelial hyperplasia, structure type III; and grade B: contrast enhancement or endothelial hyperplasia, structure type II and III).

[MeSH-minor] Astrocytoma / pathology. Humans. Neoplasms, Complex and Mixed / classification. Neoplasms, Complex and Mixed / pathology. Oligodendroglioma / pathology. Reproducibility of Results. World Health Organization

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15888386.001).

[ISSN] 1769-6917

[Journal-full-title] Bulletin du cancer

[ISO-abbreviation] Bull Cancer

[Language] fre

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] France

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Supratentorial pilocytic astrocytoma in children.

Histopathological examination revealed the typical grade I pilocytic astrocytoma.

[MeSH-major] Astrocytoma / pathology. Supratentorial Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20809042.001).

[ISSN] 1220-0522

[Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie

[ISO-abbreviation] Rom J Morphol Embryol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Romania

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A sequential scanning of the immune efficiency in astrocytoma (Grade I to Grade Iii), meningioma and secondary glioma patients with and without therapeutic scheduling.

Thus, the study aims at evaluating the sequential immune status of glioma bearing patients (Astrocytoma Grade I to Grade III) receiving conventional therapeutic measures.

METHODS: Functional immune parameters of peripheral blood lymphocytes were assayed by CD2 receptors enumeration through E-rosetting and lymphocyte cytotoxicity assay and assessing the generation of reactive oxygen species by NBT assay of peripheral blood macrophages in patient groups bearing Astrocytoma (Grade I to Grade III), meningioma and secondary glioma.

RESULTS: Patients bearing Astrocytoma (all 3 grades) showed maximum immune suppression as compared to the normal subjects, diseased meningioma controls, and secondary glioma.

However, therapeutic scheduling could recover the functional activity of the CD8 bearing lymphocytes and the CD56 NK cells from that of tumor bearing patients.

CONCLUSION: Astrocytoma and not meningioma is capable of causing immunesuppression.

As the tumor progresses from Grade I to Grade III, a linear reduction in the functional efficacy of immunocytes is seen to occur.

The inhibitory effect of tumor as well as of therapy were mainly directed towards the CD2 bearing lymphocyte population and the peripheral blood macrophage population.

[MeSH-major] Astrocytoma / immunology. Central Nervous System Neoplasms / immunology. Glioma / immunology. Immune Tolerance. Meningioma / immunology

[MeSH-minor] Antigens, CD2 / analysis. Antineoplastic Agents / adverse effects. Cytotoxicity Tests, Immunologic. Humans. Macrophages / immunology. Neoplasm Invasiveness. Phagocytosis. Radiotherapy / adverse effects. Rosette Formation. T-Lymphocytes, Cytotoxic / immunology

Genetic Alliance. consumer health - Glioma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16939959.001).

[ISSN] 0735-7907

[Journal-full-title] Cancer investigation

[ISO-abbreviation] Cancer Invest.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD2; 0 / Antineoplastic Agents

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Juvenile pilocytic astrocytomas do not undergo spontaneous malignant transformation: grounds for designation as hamartomas.

AIM: To determine whether juvenile pilocytic astrocytomas WHO grade I have the potential for spontaneous malignant transformation.

METHODS: A literature search was performed, cross-referencing juvenile pilocytic astrocytoma, pilocytic astrocytoma, astrocytoma grade I, optic glioma, glioma, low-grade gliomas, polar spongioblastoma, gliocytoma embryonale, and malignant transformation, anaplasia or anaplastic change.

Twenty-two of these tumours, however, did not initially match criteria for juvenile pilocytic astrocytoma WHO grade I and were excluded.

CONCLUSION: Juvenile pilocytic astrocytomas WHO grade I do not undergo spontaneous anaplastic transformation.

Earlier clinical and histopathological opinions regarding juvenile pilocytic astrocytomas as hamartomatous lesions are reaffirmed.

[MeSH-major] Astrocytoma / pathology. Brain Diseases / pathology. Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Hamartoma / pathology

MedlinePlus Health Information. consumer health - Brain Diseases.

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17962395.001).

[ISSN] 1468-2079

[Journal-full-title] The British journal of ophthalmology

[ISO-abbreviation] Br J Ophthalmol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Number-of-references] 90

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Polysialic acid overexpression in malignant astrocytomas.

METHODS: Intra-operatively collected biopsies from 30 patients with different astrocytoma grades were immuno-histochemically examined to identify expression of PSA.

RESULTS: Astrocytoma grade I and II had 4% PSA expressing cells whereas in grade III and IV the number of PSA expressing cells was 45%.

CONCLUSION: In this short communication we show that highly malignant astrocytomas express significantly more PSA compared to less malignant astrocytomas.

[MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Sialic Acids / metabolism

[MeSH-minor] Animals. Biopsy. Cell Adhesion / physiology. Cell Differentiation / physiology. Cell Movement / physiology. Cell Proliferation. Disease Models, Animal. Humans. Immunohistochemistry. Mice. Neoplasm Invasiveness / diagnosis. Neoplasm Invasiveness / physiopathology. Neoplasm Proteins / physiology. Nerve Tissue Proteins / physiology. Neural Cell Adhesion Molecules / metabolism. Stem Cells / cytology. Stem Cells / metabolism

MedlinePlus Health Information. consumer health - Brain Tumors.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19387537.001).

[ISSN] 0942-0940

[Journal-full-title] Acta neurochirurgica

[ISO-abbreviation] Acta Neurochir (Wien)

[Language] eng

[Publication-type] Journal Article

[Publication-country] Austria

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Neural Cell Adhesion Molecules; 0 / Sialic Acids; 0 / UCC1 protein, human; 0 / polysialic acid

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: We reviewed 68 cases of intramedullary tumors (ependymoma, 33; astrocytoma, 23; hemangioblastoma, 12), treated surgically between 1994 and 2003.

The tumor malignancy grade according to the WHO classification was astrocytoma grade I, 3; grade II, 8 (low-grade: 11 cases); grade III, 10; grade IV, 2 (high-grade: 12 cases).

All ependymomas were grade II.

Approximately 50% of low-grade astrocytomas could be totally excised with favorable survival outcomes, suggesting that total excision should be attempted for low-grade astrocytomas.

However, total excision of high-grade tumors was difficult and the functional outcomes were poor.

Cordotomy should be considered in patients with a thoracic high-grade astrocytoma.

[MeSH-major] Astrocytoma / surgery. Ependymoma / surgery. Hemangioblastoma / surgery. Spinal Cord Neoplasms / surgery

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17909556.001).

[ISSN] 1362-4393

[Journal-full-title] Spinal cord

[ISO-abbreviation] Spinal Cord

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

One minute downward pressure on the tip of any one of the front 3 teeth (1st incisor, 2nd incisor, and canine) at the right and left sides of the upper and lower jaw by a wooden toothpick induced temporary disappearance (20 min approximately 4 hours) of abnormally increased pain parameters (pain grading, Substance P, & TXB2), and cancer parameters (Telomere, Integrin alpha5beta1, Oncogene C-fos Ab2, etc. of Astrocytoma, Glioblastoma, squamous cell carcinoma of esophagus, adenocarcinoma of lung, breast cancer, adenocarcinoma of colon, prostate cancer).

Increasing NC telomere to optimally high level resulted in disappearance of pain and improvement or significant reduction of malignant tumor.

One optimal dose of Boswellia Serrata or Astragalus not only increased NC telomere 650 ng BDORT units, eliminating pain and cancer parameters, but also reduced the size of the Astrocytoma grade I by 10-20% and the Glioblastoma by 15-90% in less than 2-6 months in some patients, as long as high NC telomere is maintained.

MedlinePlus Health Information. consumer health - Acupuncture.

MedlinePlus Health Information. consumer health - Pain.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20344885.001).

[ISSN] 0360-1293

[Journal-full-title] Acupuncture & electro-therapeutics research

[ISO-abbreviation] Acupunct Electrother Res

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Drugs, Chinese Herbal

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Residual or recurrent cerebellar low-grade glioma in children after tumor resection: is re-treatment needed? A single center experience from 1983 to 2003.

PURPOSE: The aim of this study was to report on children with cerebellar low-grade glioma (LGG), who were found to have progressive or nonprogresssive residual tumors or tumor recurrence after tumor resection.

RESULTS: Of 289 patients with CNS tumors referred between 1983 and 2003, 28 (9.7%) (15 male, 13 female; median age at diagnosis: 71 months) had cerebellar LGG (pilocytic astrocytoma grade I: n = 21; fibrillary astrocytoma grade II: n = 5; mixed hamartoma/pilocytic astrocytoma: n = 1; radiographic diagnosis: n = 1).

CONCLUSIONS: A 'wait and see' strategy is justified in patients with nonprogressive recurrent or residual cerebellar LGG after primary tumor resection.

[MeSH-major] Astrocytoma / surgery. Cerebellar Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2006 S. Karger AG, Basel

(PMID = 16636617.001).

[ISSN] 1016-2291

[Journal-full-title] Pediatric neurosurgery

[ISO-abbreviation] Pediatr Neurosurg

[Language] eng

[Publication-type] Journal Article

[Publication-country] Switzerland

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] 11C-Methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas.

OBJECTIVE: The treatment regimen for cerebral gliomas is different, depending on the histological grade of the lesion.

The management for low-grade gliomas is still under discussion, operation or "wait and see" tactics are possible options.

Although most of the low-grade gliomas appear as hypointense lesions without contrast medium (CM) enhancement on magnetic resonance images, in some cases lesions without CM enhancement can be anaplastic tumours as well.

11C-Methionine positron emission tomography (MET-PET) was performed for preoperative evaluation of non or low CM enhancing intracerebral lesions, so-called suggestive low-grade gliomas.

METHOD: 20 patients harbouring suggestive low-grade gliomas were included.

Histologically the 2 patients with sparse CM enhancement and MET uptake were glioblastoma multiforme, 10/14 patients with MET uptake and without CM enhancement had an anaplastic astrocytoma WHO III, 3/14 with MET uptake and no CM enhancement had an anaplastic oligoastrocytoma WHO III, and 1/14 had an oligoastrocytoma grade II.

The lesions of the 4 patients without MET uptake and without CM enhancement were classified as astrocytoma grade II in 2 cases, as astrocytoma grade I in 1 case and as astrocytoma III in one case.

CONCLUSION: According to the results of this study, we find MET-PET to be a helpful tool for pretreatment evaluation of non-CM enhancing, suggestive low-grade intracerebral lesions.

[MeSH-minor] Astrocytoma / radionuclide imaging. Astrocytoma / surgery. Glioblastoma / radionuclide imaging. Glioblastoma / surgery. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Neurosurgical Procedures. Positron-Emission Tomography

MedlinePlus Health Information. consumer health - Brain Tumors.

Hazardous Substances Data Bank. (L)-Methionine .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17487804.001).

[ISSN] 0044-4251

[Journal-full-title] Zentralblatt für Neurochirurgie

[ISO-abbreviation] Zentralbl. Neurochir.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Radiopharmaceuticals; AE28F7PNPL / Methionine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

64% had grade 4 astrocytoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962817.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: e13003 Background: Chromosomes 1p/19q codeletion has been recognized as a prognostic and predictive factor in patients (pts) with grade 3 gliomas.

Non-codeleted (intact) anaplastic oligodendroglioma showed a survival comparable to that usually observed in pts with anaplastic astrocytomas; MGMT methylation status, moreover, has been found to be a prognostic factor in glioblastoma and anaplastic gliomas (AG).

Histology was anaplastic oligodendroglioma in 17 pts, anaplastic oligoastrocytoma in 20 pts, and anaplastic astrocytoma in 30 pts; all these pts were 1p19q intact and received surgery, RT, and CT.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962754.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG).

METHODS: Eligibility included: adult patients with stable or recurrent MG (GBM, anaplastic astrocytoma [AA], anaplastic oligodendroglioma [AO]) previously treated with radiation therapy (RT) and with or without chemotherapy; interval of at least two weeks between prior RT, or four weeks between prior chemotherapy; Karnofsky ≥ 60%; and adequate hematologic, renal and liver function.

Dose-limiting toxicities were: deep venous thrombosis (1 grade 3); nausea and vomiting (1 grade 3); diarrhea (1 grade 3); elevated ALT (1 grade 3); elevated creatinine (1 grade 3); and fatigue (1 grade 3).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962751.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: e13037 Background: Anaplastic astrocytoma (AA), oligodendroglioma (AOD), and oligoastrocytoma (AOA) are rare tumors showing variable outcome due to their histological heterogeneity and different chemo- and radio-sensitivity.

Nine pts (32%) underwent tumor complete resection, 10 partial resection (36%), and 9 (32%) tumor biopsy.

Frequent mild toxicities were grade 1-2 nausea/vomiting (17 pts-63%), and grade 1-2 asthenia (8 pts-30%).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962859.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Efficacy of protracted dose-dense temozolomide (TMZ) in patients with progressive high-grade glioma.

: e13018 Background: The study was aimed to evaluate the efficacy of TMZ on a protracted dose-dense schedule after standard 5-day TMZ regimen in patients with progressive high-grade glioma.

METHODS: In this phase II prospective study, patients who had progression on standard 5-day TMZ for recurrence (group 1) or recurrence after concurrent radiotherapy+TMZ and ≥ 2 cycles of adjuvant TMZ (group 2) for high-grade glioma received TMZ 100 mg/m2× 21 q28 days until progression according to MacDonald's criteria.

The histopathology was glioblastoma in 18 and grade 3 glioma (anaplastic astrocytoma, anaplastic oligoastrocytoma or anaplastic oligodendroglioma) in 7.

Out of 80 cycles received there was no anemia; 5 (6%) grade 1, 8 (10%) grade 2, 2 (3%) grade 3 leucopenia; 1 (1%) grade 1, 2 (3%) grade 2, 1 (1%) grade 3, 1 (1%) grade 4 thrombocytopenia; 9 (11%) grade 1, 7 (9%) grade 2, 32 (40%) grade 3, and 11 (14%) grade 4 lymphopenia.

Study was terminated in 2 patients (one with grade 4 thrombocytopenia and the other with grade 4 hepatic toxicity).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962826.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] DNA methylation pattern of brain stem pilocytic astrocytomas in children.

: 10021 Background: Pilocytic astrocytoma (WHO grade I) comprises the most frequent brain tumor in childhood.

METHODS: To identify novel genes involved in astrocytoma pathogenesis, we performed a genome-wide DNA methylation analysis of 78 pilocytic astrocytoma samples from different tumor locations (diencephalic, cerebral, cerebellar, brain stem).

Genes contained in the signature most interestingly included three homeobox family genes (HOXB1, HOXD3, and HOXD4), and NES, a tumor stem cell marker.

CONCLUSIONS: These data suggest that brain stem pilocytic astrocytomas display biologic features different from most tumors of other locations and share a methylation signature with tumors prone to disease recurrence from other locations.

We provide first evidence for a role of differentially methylated homeobox family genes in the pathogenesis of pilocytic astrocytoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962622.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.

: 2033 Background: Our prior immunotherapy trials demonstrated efficacy in generating a tumor specific immune response in malignant glioma and the potential for high tumor-specific toxicity and sustained tumoricidal activity.

METHODS: We exploited this synergistic effect to maintain a cytotoxic environment around the tumor milieu.

Patients with high-grade glioma were eligible after maximal resection with biodegradable carmustine (BCNU) wafer placement.

Screening leukapheresis is used to isolate mononuclear cells which are differentiated into dendritic cells, pulsed with tumor lysate, and then 3 intradermal vaccines are administered at 2-week intervals.

The histology included 3 newly diagnosed glioblastoma multiforme (GBM), 8 recurrent GBM, 2 newly diagnosed anaplastic astrocytoma (AA), and 2 recurrent AA.

Our preliminary data on 15 patients and 39 courses of Dendritic Cell vaccines demonstrate one grade 3 toxicity of fever/chest pain.

CONCLUSIONS: This phase I study demonstrates the safety, feasibility of dendritic cell vaccination with biodegradable carmustine (BCNU) wafers with one grade 3 AE.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964627.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

For example, gliomas of astrocytic origin (astrocytomas) are classified into pilocytic astrocytoma (grade I), astrocytoma (grade II), anaplastic astrocytoma (grade III) and glioblastoma multiforme (GMB) (grade IV).

Tumors derived from oligodendrocytes include grade II (oliogodendrogliomas) and grade III neoplasms (oligoastrocytoma).

Furthermore, the ability that allows several low-grade gliomas to progress into more aggressive tumors has allowed cancer researchers to elucidate several pathways implicated in molecular biology of these devastating tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Neoplasia. 2005 Jan;7(1):7-16 [15720813.001]

[Cites] Am J Pathol. 2003 Sep;163(3):1033-43 [12937144.001]

[Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]

[Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8 [16039986.001]

[Cites] Cell. 1995 Dec 15;83(6):993-1000 [8521522.001]

[Cites] Cancer Res. 2005 May 15;65(10):4088-96 [15899798.001]

[Cites] Cancer Res. 2001 Sep 15;61(18):6674-8 [11559533.001]

[Cites] Cell Cycle. 2006 Apr;5(7):783-91 [16582634.001]

[Cites] Int J Cancer. 2006 Aug 15;119(4):792-800 [16550607.001]

[Cites] Cancer Treat Rev. 2004 Apr;30(2):193-204 [15023437.001]

[Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]

[Cites] Nat Genet. 2000 May;25(1):55-7 [10802656.001]

[Cites] Int J Cancer. 1995 Aug 9;62(4):386-92 [7635563.001]

[Cites] Mol Cancer Ther. 2002 Nov;1(13):1229-36 [12479704.001]

[Cites] Cancer Cell. 2003 Apr;3(4):311-6 [12726857.001]

[Cites] Cancer Cell. 2002 Apr;1(3):269-77 [12086863.001]

[Cites] Physiol Genomics. 2001 Feb 07;5(1):21-33 [11161003.001]

[Cites] Cancer Res. 2000 Dec 1;60(23):6617-22 [11118044.001]

[Cites] Oncogene. 2003 Dec 8;22(56):9030-40 [14663481.001]

[Cites] Cancer Res. 2005 May 15;65(10 ):4051-8 [15899794.001]

[Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):212-21 [14734472.001]

[Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]

[Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]

[Cites] Cancer Res. 1997 Oct 1;57(19):4183-6 [9331071.001]

[Cites] J Neuropathol Exp Neurol. 1998 Feb;57(2):122-30 [9600204.001]

[Cites] Genes Dev. 1998 Dec 1;12(23):3644-9 [9851971.001]

[Cites] Cell. 2004 Apr 16;117(2):211-23 [15084259.001]

[Cites] J Neurooncol. 1998 Jan;36(2):123-40 [9525812.001]

[Cites] Cancer Res. 1995 May 1;55(9):1941-5 [7728764.001]

[Cites] Oncogene. 2001 Mar 1;20(9):1103-9 [11314047.001]

[Cites] Cancer Res. 1994 Nov 15;54(22):5804-7 [7954404.001]

[Cites] Oncogene. 2004 Jun 3;23 (26):4594-602 [15077177.001]

[Cites] Cancer Res. 2001 Sep 15;61(18):6885-91 [11559565.001]

[Cites] Genes Chromosomes Cancer. 1994 Oct;11(2):91-6 [7529554.001]

[Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]

[Cites] J Neuropathol Exp Neurol. 1994 Jan;53(1):11-21 [8301315.001]

(PMID = 17005465.001).

[ISSN] 1699-048X

[Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

[ISO-abbreviation] Clin Transl Oncol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] Italy

[Number-of-references] 36

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The efficacy of radiation therapy in the management of grade I astrocytomas.

INTRODUCTION: The purpose of this study was to analyze the outcome of patients with grade I astrocytomas treated with radiation therapy, specifically looking at the prognostic significance of age, timing of radiation therapy (immediately after surgery or delayed until progression) and tumor location.

MATERIALS AND METHODS: The records of patients with grade I astrocytomas treated at Washington University Medical Center between 1982 and 2002 were reviewed.

Twenty patients with grade I pilocytic astrocytoma (n=19) or subependymal giant cell astrocytoma (n=1) were treated with radiation therapy with curative intent.

All tumor recurrences were local.

CONCLUSIONS: While this study reports an excellent overall survival, approximately one third of patients with grade I astrocytomas had progressive disease following radiation therapy.

[MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Neoplasm Recurrence, Local

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer. 1979 Jul;44(1):276-80 [455252.001]

[Cites] J Neurosurg. 1985 Jun;62(6):811-5 [3998829.001]

[Cites] J Clin Oncol. 1997 Aug;15(8):2792-9 [9256121.001]

[Cites] Cancer. 1985 Mar 1;55(5):919-27 [3967199.001]

[Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]

[Cites] J Neurosurg. 1989 Jun;70(6):853-61 [2715812.001]

[Cites] J Neurosurg. 1988 Aug;69(2):171-6 [3392563.001]

[Cites] Cancer. 1973 Sep;32(3):646-55 [4199356.001]

[Cites] Childs Nerv Syst. 1995 Feb;11(2):89-96 [7758018.001]

[Cites] J Neurosurg. 1995 Apr;82(4):536-47 [7897512.001]

[Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56 [8948338.001]

[Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):661-4 [2809719.001]

[Cites] Childs Nerv Syst. 1995 Aug;11(8):438-42 [7585678.001]

[Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):704-10 [11597812.001]

[Cites] Int J Radiat Oncol Biol Phys. 1990 Apr;18(4):815-8 [2323970.001]

[Cites] Oncology (Williston Park). 1993 Jul;7(7):97-104, 107; discussion 108-11 [8347464.001]

[Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]

[Cites] Pediatr Neurosurg. 2001 Dec;35(6):311-7 [11786699.001]

(PMID = 16132503.001).

[ISSN] 0167-594X

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Survival and functional outcome of childhood spinal cord low-grade gliomas. Clinical article.

OBJECT: Intramedullary spinal cord low-grade gliomas (LGGs) are rare CNS neoplasms in pediatric patients, and there is little information on therapy for and outcome of these tumors in this population.

Furthermore, most patient series combine adult and pediatric patients or high- and low-grade tumors, resulting in controversial data regarding optimal treatment of these children.

Histological testing revealed a Grade I astrocytoma in 86% of tumors.

Chemotherapy and radiation therapy showed similar efficacy, achieving sustained tumor control in most patients.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19772410.001).

[ISSN] 1933-0707

[Journal-full-title] Journal of neurosurgery. Pediatrics

[ISO-abbreviation] J Neurosurg Pediatr

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The expression of the O-linked N-acetylglucosamine containing epitope H in the gemistocytic, pilocytic and subependymal giant cell astrocytomas.

In normal human brains the epitope H is present mostly to a minority of fibrous astrocytes, whereas it is greatly up-regulated in reactive astrocytes and is increased in well differentiated fibrillary astrocytomas compared to anaplastic astrocytomas and glioblastomas.

In this study the expression of the epitope H was investigated in thirty cases of gemistocytic (WHO grade II), pilocytic (WHO grade I), and subependymal giant cell (WHO grade I) astrocytomas using the mAbH with the indirect immunoperoxidase method.

The ten cases of gemistocytic astrocytomas revealed an overall high expression pattern.

The ten cases of pilocytic astrocytomas revealed a biphasic pattern of epitope H expression.

The dense tumor areas composed of elongated pilocytic cells revealed high expression of the epitope H.

The loose cystic tumor areas composed of stellate cells revealed low expression of the epitope H.

The ten cases of subependynal giant cell astrocytomas occurring in tuberous sclerosis revealed an overall high expression pattern.

This study shows that there is high expression of the epitope H in gemistocytic, pilocytic and subependymal giant cell astrocytomas.

Collectively considering, the present and our previous data, it appears that there is a spectrum of the expression levels of the epitope H ranging from the high expression in the reactive astrocytes and low grade astrocytomas to the low/null expression in the normal astrocytes and glioblastomas.

[MeSH-major] Acetylglucosamine / analysis. Astrocytoma / chemistry. Brain Neoplasms / chemistry. Epitopes

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19639198.001).

[ISSN] 1021-335X

[Journal-full-title] Oncology reports

[ISO-abbreviation] Oncol. Rep.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Greece

[Chemical-registry-number] 0 / Epitopes; V956696549 / Acetylglucosamine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Exploring the distinctive biological characteristics of pilocytic and low-grade diffuse astrocytomas using microarray gene expression profiles.

Although World Health Organization (WHO) grade I pilocytic astrocytomas and grade II diffuse astrocytomas have been classified for decades as different clinicopathologic entities, few, if any, data are available on the biologic features explaining these differences.

Although more than 50 microarray-related studies have been carried out to characterize the molecular profiles of astrocytic tumors, we have identified only 11 that provide sound data on low-grade astrocytomas.

We have incorporated these data into a comparative analysis for the purpose of identifying the most relevant molecular markers characterizing grade I pilocytic and grade II diffuse astrocytomas.

Our analysis has identified various interesting genes that are differentially expressed in either grade I or grade II astrocytomas when compared with normal tissue and/or high-grade (WHO grade III and IV) astrocytomas.

Interestingly, a group of 6 genes (TIMP4, C1NH, CHAD, THBS4, IGFBP2, and TLE2) constitute an expression profile characteristic of grade I astrocytomas as compared with all other categories of tissue (normal brain, grade II, and high-grade astrocytomas).

The end products (proteins) of these genes act as antimigratory compounds, a fact that could explain why pilocytic astrocytomas behave as compact (well-circumscribed) tumors as opposed to all the other astrocytic tumor types that diffusely invade the brain parenchyma.

Having validated these molecular markers by means of real-time reverse transcriptase-polymerase chain reaction, an integrated model was proposed illustrating how and why pilocytic astrocytomas constitute a distinct biologic and pathologic entity when compared with diffuse astrocytomas.

[MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic / genetics. Genetic Predisposition to Disease / genetics

[MeSH-minor] Adult. Cell Adhesion / genetics. Cell Movement / genetics. Child. Extracellular Matrix Proteins / genetics. Extracellular Matrix Proteins / metabolism. Humans. Models, Neurological. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / physiopathology. Oligonucleotide Array Sequence Analysis / methods. Reverse Transcriptase Polymerase Chain Reaction

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16896313.001).

[ISSN] 0022-3069

[Journal-full-title] Journal of neuropathology and experimental neurology

[ISO-abbreviation] J. Neuropathol. Exp. Neurol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We examined the expression of Beclin 1 protein in 212 primary human brain tumours, including 97 high-grade glial tumours, 29 low-grade glial tumours, 4 grade III meningiomas, 19 grade II meningiomas, 52 grade I meningiomas, and 11 medulloblastomas.

In most high-grade astrocytic, ependymal neoplasms and atypical meningiomas we found a decrease of cytoplasmic protein expression that was, instead, high in the majority of low-grade tumours and in medulloblastomas.

The expression level of Beclin 1 mRNA was significantly lower in glioblastomas than in grade II (p=0.04) and grade I (p=0.01) astrocytomas; in grade III than in grade I astrocytomas (p=0.01); in grade II than in grade I meningiomas (p=0.03); and in all glial tumours when compared to all meningiomas (p<0.0001).

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17203225.001).

[ISSN] 1019-6439

[Journal-full-title] International journal of oncology

[ISO-abbreviation] Int. J. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Greece

[Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BECN1 protein, human; 0 / Membrane Proteins; 0 / RNA, Messenger

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma.

The aim of the study was to analyze the expression of OPN in human astrocytomas and to correlate it with angiogenesis and patients' outcome.

Seventy-six human astrocytomas including eight pilocytic astrocytomas (grade I), 10 diffuse astrocytomas (grade II), 8 anaplastic astrocytomas (grade III) and 50 glioblastomas (grade IV) were immunohistochemically stained for OPN protein.

Astrocytomas were heterogeneous regarding the OPN expression.

Our results indicate the overexpression of OPN protein in astrocytoma cells and suggest the role of OPN in astrocytoma progression and angiogenesis.

[MeSH-major] Astrocytoma / blood supply. Astrocytoma / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / blood supply. Brain Neoplasms / metabolism. Neovascularization, Pathologic / metabolism. Osteopontin / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Respir Crit Care Med. 1999 Oct;160(4):1269-73 [10508818.001]

[Cites] Stroke. 1998 Aug;29(8):1698-706; discussion 1707 [9707214.001]

[Cites] J Surg Oncol. 2006 Sep 15;94(4):325-31 [16917865.001]

[Cites] Br J Cancer. 2000 Jun;82(12):1967-73 [10864205.001]

[Cites] J Vet Med Sci. 2004 Oct;66(10):1307-10 [15528873.001]

[Cites] Oncogene. 1999 Jul 22;18(29):4237-46 [10435636.001]

[Cites] FASEB J. 1993 Dec;7(15):1475-82 [8262332.001]

[Cites] Am J Pathol. 1996 Jul;149(1):293-305 [8686754.001]

[Cites] Cancer Res. 2002 Aug 15;62(16):4820-8 [12183442.001]

[Cites] Oncogene. 2006 May 4;25(19):2818-26 [16314830.001]

[Cites] Brain Res. 2005 Apr 11;1041(1):95-101 [15804504.001]

[Cites] J Cell Biochem. 1994 Sep;56(1):48-51 [7528752.001]

[Cites] Cancer Lett. 2003 Jul 30;198(1):107-17 [12893437.001]

[Cites] Cancer Res. 2002 Jun 15;62(12):3417-27 [12067984.001]

[Cites] Anticancer Res. 1998 Mar-Apr;18(2A):807-12 [9615723.001]

[Cites] Lab Invest. 1995 Jan;72(1):55-63 [7837791.001]

[Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90 [14734468.001]

[Cites] Mol Cell Biol. 2000 Apr;20(8):2734-42 [10733576.001]

[Cites] J Cell Biol. 1998 May 18;141(4):1083-93 [9585425.001]

[Cites] Leukemia. 2005 Dec;19(12):2166-76 [16208410.001]

[Cites] J Neurooncol. 2001 Jun;53(2):161-76 [11716068.001]

[Cites] Oncogene. 2003 Feb 27;22(8):1198-205 [12606946.001]

[Cites] Cancer Res. 2002 Sep 15;62(18):5336-43 [12235004.001]

[Cites] Neuropathol Appl Neurobiol. 2005 Jun;31(3):292-303 [15885066.001]

[Cites] Front Biosci. 1999 Feb 15;4:D188-99 [9989953.001]

[Cites] J Natl Cancer Inst. 1993 Feb 3;85(3):200-6 [8423624.001]

[Cites] Br J Cancer. 2004 May 17;90(10):1877-81 [15138464.001]

[Cites] Radiother Oncol. 2007 Jun;83(3):398-405 [17524506.001]

[Cites] Am J Pathol. 2006 May;168(5):1676-85 [16651633.001]

(PMID = 18493866.001).

[ISSN] 1219-4956

[Journal-full-title] Pathology oncology research : POR

[ISO-abbreviation] Pathol. Oncol. Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression and activity of l-isoaspartyl methyltransferase decrease in stage progression of human astrocytic tumors.

Here we investigated PIMT regulation in astrocytic tumors, which are the most common human brain tumors.

PIMT expression and enzyme activity were significantly decreased in all grades of human astrocytic tumors.

More precisely, PIMT levels were significantly lower by 76% in pilocytic astrocytomas (grade I), 46% in astrocytomas (grade II), 69% in anaplastic astrocytomas (grade III), and a marked 80% in glioblastomas (grade IV) as compared to normal brains.

Furthermore, the reduced PIMT levels correlated closely with a decrease in the number of neuron cells in astrocytic tumors as assessed by measuring the neuron-specific enolase level.

Many proteins with abnormal aspartyl residues accumulated in brain tumors and some were specific to individual grades of astrocytic tumors.

Similar results were obtained, either by measuring the reduction in PIMT activity and expression or by measuring the formation of abnormal proteins, in an orthotopic rat brain tumor model implanted with invasive CNS-1 glioma cells.

The novelty of these findings was to provide the first evidence for a marked reduction of PIMT expression and activity during stage progression of astrocytic tumors in humans.

[MeSH-minor] Animals. Blotting, Northern. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry / methods. Male. Methylation. Neoplasm Transplantation / methods. Phosphopyruvate Hydratase / metabolism. RNA, Messenger / metabolism. Rats. Rats, Inbred Lew. Reverse Transcriptase Polymerase Chain Reaction / methods

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15857672.001).

[ISSN] 0169-328X

[Journal-full-title] Brain research. Molecular brain research

[ISO-abbreviation] Brain Res. Mol. Brain Res.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / RNA, Messenger; EC 2.1.1.77 / Protein D-Aspartate-L-Isoaspartate Methyltransferase; EC 4.2.1.11 / Phosphopyruvate Hydratase

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Histomorphometry of tumour cell nuclei in astrocytomas using shape analysis, densitometry and topometric analysis.

Although tumour cell nuclei are important histological structures for grading of astrocytomas according to the WHO-classification of brain tumours, there is no reported morphometric study of astrocytomas which describes quantitatively the four main morphologic criteria of tumour cell nuclei: size, shape, texture (densitometric characteristics) and spatial relationships between the nuclei (topometric analysis).

Using a set of morphometric parameters describing these criteria as well as the Ki67-proliferation index, 74 astrocytomas from 74 patients were studied by means of a digital image analysis system.

The objective of the study was to test, if these morphometric parameters were sufficient for statistical discrimination between pilocytic astrocytomas WHO-grade I, astrocytomas grade II and anaplastic astrocytomas grade III.

Our results showed a correct reclassification of 97.3% (72/74) of the cases with respect to the tumour grade by means of cross-validated discriminant analysis.

In conclusion, the present morphometric procedure provided good discrimination between the tumour grades, supporting the view that histomorphometry of tumour cell nuclei could be a valuable tool for grading of astrocytomas.

[MeSH-major] Astrocytoma / pathology. Astrocytoma / ultrastructure. Brain Neoplasms / pathology. Brain Neoplasms / ultrastructure. Cell Nucleus / pathology. Cell Nucleus / ultrastructure

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15634229.001).

[ISSN] 0305-1846

[Journal-full-title] Neuropathology and applied neurobiology

[ISO-abbreviation] Neuropathol. Appl. Neurobiol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Postoperative radiotherapy results in primary spinal cord astrocytomas.

BACKGROUND AND PURPOSE: We retrospectively evaluated the therapeutic outcomes of patients with primary spinal cord astrocytomas treated with conventional radiotherapy at our institute.

PATIENTS AND METHODS: Between May 1975 and December 1997, 26 patients with histologically proven spinal cord astrocytomas were treated with conventional radiotherapy, and twenty-four eligible patients were evaluated.

Fourteen of astrocytomas were grade I, 6 of them grade II and 4 grade III.

Patients were treated with 1-2 Gy daily fractions, and given to a median total dose of 49.5 Gy (range 35-60 Gy) external radiotherapy to primary tumor.

[MeSH-major] Astrocytoma / radiotherapy. Spinal Cord Neoplasms / radiotherapy

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15683668.001).

[ISSN] 0167-8140

[Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

[ISO-abbreviation] Radiother Oncol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Ireland

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

However, 14-3-3 immunoreactivity was seen in the majority of astrocytomas [grade I (9/11), II (16/21), III (13/17), IV (17/21)].

There was no difference between the positive expression rates of 14-3-3 in different grades of astrocytomas (P = 0.968).

But the intensity and degree of 14-3-3 immunoreactivity in diffuse astrocytomas, anaplastic astrocytoma, and glioblastoma multiformes showed trends with tumor grade, with glioblastomas having the highest positivity (P = 0.048).

[MeSH-major] 14-3-3 Proteins / biosynthesis. Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism

MedlinePlus Health Information. consumer health - Brain Tumors.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Biochem J. 2004 Apr 15;379(Pt 2):395-408 [14744259.001]

[Cites] J Neurosurg. 2002 Sep;97(3):668-75 [12296652.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8511-5 [10411906.001]

[Cites] Pathol Res Pract. 2002;198(12):813-9 [12608658.001]

[Cites] Exp Cell Res. 2001 Nov 15;271(1):142-51 [11697890.001]

[Cites] Am J Pathol. 1999 Mar;154(3):767-74 [10079254.001]

[Cites] J Neurochem. 1982 May;38(5):1475-82 [7062063.001]

[Cites] Cell. 1996 Nov 15;87(4):619-28 [8929531.001]

[Cites] Expert Rev Anticancer Ther. 2005 Feb;5(1):177-91 [15757449.001]

[Cites] FEBS Lett. 1993 Oct 4;331(3):296-303 [8375512.001]

[Cites] EMBO J. 2000 Feb 1;19(3):349-58 [10654934.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10142-6 [7479742.001]

[Cites] J Neurochem. 1982 May;38(5):1466-74 [7038050.001]

[Cites] Acta Neuropathol. 2004 Feb;107(2):137-43 [14605832.001]

[Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(2):127-47 [2424168.001]

[Cites] Annu Rev Pharmacol Toxicol. 2000;40:617-47 [10836149.001]

[Cites] Nat Rev Cancer. 2003 Dec;3(12):931-43 [14737123.001]

[Cites] J Biol Chem. 2003 Jan 17;278(3):2058-65 [12426317.001]

[Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1143-51 [11007952.001]

[Cites] FASEB J. 2003 Apr;17(6):767-9 [12594176.001]

[Cites] J Biol Chem. 1997 Apr 25;272(17):11663-9 [9111084.001]

[Cites] Biochem Soc Trans. 2002 Aug;30(4):387-91 [12196100.001]

[Cites] Annu Rev Med. 1997;48:267-81 [9046961.001]

[Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):245-53 [11895039.001]

[Cites] Neurol Med Chir (Tokyo). 1994 Jul;34(7):429-35 [7526231.001]

[Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]

[Cites] Bioessays. 2001 Oct;23(10):936-46 [11598960.001]

[Cites] Mol Cell. 2003 Jan;11(1):11-23 [12535517.001]

[Cites] Ann Neurol. 2002 Dec;52(6):722-31 [12447925.001]

[Cites] Biochem Soc Trans. 2002 Aug;30(4):360-5 [12196095.001]

[Cites] Trends Biochem Sci. 1992 Dec;17(12):498-501 [1471260.001]

(PMID = 16292484.001).

[ISSN] 0167-594X

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / YWHAB protein, human

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma.

OBJECTIVE: Independent studies have previously demonstrated that both the HIPK2 and BRAF genes are amplified and rearranged, respectively, in pilocytic astrocytomas (PAs).

CONCLUSIONS: BRAF rearrangement represents the most common genetic alteration in sporadic, but not neurofibromatosis type 1-associated, pilocytic astrocytomas (PAs).

These findings implicate BRAF in the pathogenesis of these common low-grade astrocytomas in children, and suggest that PAs arise either from NF1 inactivation or BRAF gain of function.

Genetic Alliance. consumer health - Pilocytic astrocytoma.

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Br J Cancer. 2000 Mar;82(6):1218-22 [10735509.001]

[Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]

[Cites] Neuropathol Appl Neurobiol. 2000 Aug;26(4):361-7 [10931370.001]

[Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):917-20 [11556548.001]

[Cites] J Neuropathol Exp Neurol. 2002 Oct;61(10):896-902 [12387455.001]

[Cites] Bioinformatics. 2004 May 22;20(8):1233-40 [14871870.001]

[Cites] Hum Pathol. 1995 Sep;26(9):979-86 [7672798.001]

[Cites] J Pediatr. 1995 Nov;127(5):718-22 [7472822.001]

[Cites] Ann Neurol. 1997 Feb;41(2):143-9 [9029062.001]

[Cites] Cancer Genet Cytogenet. 1998 Jul 15;104(2):157-60 [9666811.001]

[Cites] Cancer Res. 2005 Jul 15;65(14):6071-9 [16024607.001]

[Cites] Neurology. 2005 Oct 25;65(8):1335-6 [16247081.001]

[Cites] Neurology. 2006 Jan 10;66(1):127-30 [16401863.001]

[Cites] Curr Opin Genet Dev. 2007 Feb;17(1):31-9 [17208430.001]

[Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]

[Cites] Cell Oncol. 2007;29(4):269-77 [17641411.001]

[Cites] Neuropediatrics. 2007 Apr;38(2):61-3 [17712732.001]

[Cites] Oncogene. 2008 Feb 7;27(7):877-95 [17724477.001]

[Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]

[Cites] Oncogene. 2008 Aug 7;27(34):4745-51 [18408760.001]

[Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]

[CommentIn] Neurology. 2009 Nov 10;73(19):1522-3 [19812379.001]

(PMID = 19794125.001).

[ISSN] 1526-632X

[Journal-full-title] Neurology

[ISO-abbreviation] Neurology

[Language] ENG

[Grant] United States / NCRR NIH HHS / RR / UL1 RR024992; United States / NCI NIH HHS / CA / P30 CA91842

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / DNA, Neoplasm; EC 2.7.1.- / HIPK2 protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf

[Other-IDs] NLM/ PMC2777068

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic significance of co-overexpression of the EGFR/IGFBP-2/HIF-2A genes in astrocytomas.

Overexpression of the EGFR, IGFBP-2 and HIF-2A genes has been observed in high-grade astrocytomas and these genes seem to be functionally related to one another.

This study aimed to define the profile of their expressions, interactions and correlation with clinical features and prognostic significance in microdissected tumor samples from 84 patients with astrocytomas of different grades and from 6 white matter non-neoplasic brain tissue sample.

EGFR, IGFBP-2 and HIF-2A gene expression levels were analyzed by quantitative real-time PCR and differed significantly between grades I-IV astrocytic tumors (P < 0.0001, P < 0.0001 and P: 0.0013, respectively) when analyzed by the Kruskal-Wallis test.

Grade I astrocytomas presented gene expression levels similar to those encountered in samples of microdissected white matter of non-neoplastic brain tissue Overexpression of the EGFR, IGFBP-2 and HIF-2A genes was significantly associated with lower 2-year survival (P: 0.009, P: 0.0002 and P: 0.008, respectively).

Co-overexpression of these genes was strongly associated with high-grade gliomas and lower survival in univariate (P < 0.0001) and multivariate (P: 0.009) analysis, suggesting that the co-expression of the EGFR/IGFBP-2/HIF-2A pathway genes may have a more important clinical and biological impact than the expression of each individual gene alone.

[MeSH-major] Astrocytoma / genetics. Basic Helix-Loop-Helix Transcription Factors / genetics. Brain Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Insulin-Like Growth Factor Binding Protein 2 / genetics. Receptor, Epidermal Growth Factor / genetics

[MeSH-minor] Adult. Child. Female. Humans. Male. Microdissection. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Clin Cancer Res. 2005 Nov 1;11(21):7658-63 [16278385.001]

[Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]

[Cites] Cancer Cell. 2005 Aug;8(2):131-41 [16098466.001]

[Cites] Endocrinology. 2001 Apr;142(4):1652-8 [11250947.001]

[Cites] Lancet. 2003 Jan 25;361(9354):323-31 [12559880.001]

[Cites] Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):78-82 [16540735.001]

[Cites] Cancer Res. 2003 Apr 15;63(8):1865-70 [12702575.001]

[Cites] Curr Opin Oncol. 2006 Jul;18(4):330-4 [16721126.001]

[Cites] Cancer Res. 2003 Oct 15;63(20):6613-25 [14583454.001]

[Cites] J Clin Pathol. 2005 Apr;58(4):361-6 [15790698.001]

[Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):860-8 [16467100.001]

[Cites] Cancer Res. 2000 Dec 15;60(24):6868-74 [11156382.001]

[Cites] Neuropathol Appl Neurobiol. 2005 Aug;31(4):384-94 [16008822.001]

[Cites] Mol Cell Biol. 2005 Jul;25(13):5675-86 [15964822.001]

[Cites] Nat Rev Neurosci. 2004 Oct;5(10):782-92 [15378038.001]

[Cites] Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:47-57 [16273354.001]

[Cites] Cancer Res. 1999 Sep 1;59(17):4228-32 [10485462.001]

[Cites] Cancer Res. 2006 Jun 15;66(12 ):6264-70 [16778202.001]

[Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1192-202 [12128120.001]

[Cites] J Clin Oncol. 2006 Mar 10;24(8):1253-65 [16525180.001]

[Cites] Leukemia. 2003 Nov;17(11):2234-7 [12931222.001]

[Cites] J Surg Oncol. 2004 Apr 1;86(1):34-40 [15048678.001]

[Cites] Nat Med. 2003 Jun;9(6):677-84 [12778166.001]

[Cites] Cancer Res. 2003 Aug 1;63(15):4315-21 [12907597.001]

[Cites] J Neurooncol. 2004 Nov;70(2):137-60 [15674475.001]

(PMID = 17285230.001).

[ISSN] 0167-594X

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / endothelial PAS domain-containing protein 1; EC 2.7.10.1 / Receptor, Epidermal Growth Factor

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cordotomy for patients with thoracic malignant astrocytoma.

OBJECT: The optimal management of malignant astrocytomas remains controversial, and the prognosis of these lesions has been dismal regardless of the administered treatment.

In this study the authors investigated the surgical outcomes of cordotomy in patients with thoracic malignant astrocytomas to determine the effectiveness of this procedure.

METHODS: Cordotomy was performed in 5 patients with glioblastoma multiforme (GBM) and 2 with anaplastic astrocytoma (AA).

In the 2 patients with GBM, cordotomy was performed 2 and 3 weeks after a partial tumor resection.

In the 2 patients with AA, the initial treatment consisted of partial tumor resection and subtotal resection combined with radiotherapy, and rostral tumor growth and progressive paralysis necessitated cordotomy 2 and 28 months later.

One patient with a secondary GBM underwent cordotomy; the GBM developed 1 year after subtotal resection and radiotherapy for a WHO Grade II astrocytoma.

In patients with thoracic GBM, even if paralysis is incomplete, cordotomy should be performed before the tumor disseminates through the CSF.

If the tumor persists, radiotherapy and chemotherapy are indicated, and cordotomy should be reserved for lesions growing progressively after such second-line treatments.

[MeSH-major] Astrocytoma / surgery. Cordotomy. Thoracic Neoplasms / surgery

[MeSH-minor] Adolescent. Adult. Disease Progression. Encephalitis / etiology. Female. Glioblastoma / complications. Glioblastoma / pathology. Glioblastoma / surgery. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Pain, Postoperative. Paraplegia / etiology. Paraplegia / surgery. Prognosis. Radiotherapy, Adjuvant. Treatment Outcome. Young Adult

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20887138.001).

[ISSN] 1547-5646

[Journal-full-title] Journal of neurosurgery. Spine

[ISO-abbreviation] J Neurosurg Spine

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The combination of low cytoplasmic and high nuclear expression of p27 predicts a better prognosis in high-grade astrocytoma.

No previous reports have examined the subcellular localization of p27 in glioma which was evaluated here regarding the prognosis in high-grade astrocytomas.

PATIENTS AND METHODS: The pattern of subcellular localization of p27 expression was examined immunohistochemically in 49 patients with high-grade astrocytoma who were over 20 years of age.

Cox multiple regression analysis showed the combination of high nuclear and low cytoplasmic p27 expression associated with a significantly better prognosis in high-grade astrocytoma.

CONCLUSION: A combination of low cytoplasmic and high nuclear expression of p27 predicts a better prognosis in high-grade astrocytomas and thus the subcellular localization of p27 expression is useful for predicting the prognosis for these patients.

[MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / biosynthesis. Brain Neoplasms / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / biosynthesis

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19331209.001).

[ISSN] 0250-7005

[Journal-full-title] Anticancer research

[ISO-abbreviation] Anticancer Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Greece

[Chemical-registry-number] 0 / Biomarkers, Tumor; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pediatric low-grade gliomas and the need for new options for therapy: Why and how?

Pediatric low-grade gliomas are the most common tumors of the central nervous system in children, accounting for almost 50% of all childhood brain tumors.

Most treatment studies address low-grade gliomas as a single entity, depriving us of histology-specific treatment outcomes.

This is mostly due to a lack of understanding of tumor biology at the molecular level.

Pediatric low-grade gliomas are not benign, and most incompletely resected tumors will progress and negatively affect quality of life.

The advancements made in understanding sporadic pilocytic astrocytoma and neurofibromatosis 1-associated pilocytic astrocytoma in particular have paved the way for potential targeted therapy and biological stratification.

Such progress in pilocytic astrocytoma needs to be consolidated and expanded to other histologic varieties of pediatric low-grade gliomas.

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Acta Neuropathol. 1993;86(1):81-5 [8103960.001]

[Cites] J Neurosurg. 1994 Jul;81(1):24-30 [8207524.001]

[Cites] Genes Chromosomes Cancer. 1995 Mar;12(3):165-72 [7536455.001]

[Cites] J Neurosurg. 1995 Jul;83(1):67-71 [7782852.001]

[Cites] Hum Pathol. 1995 Sep;26(9):979-86 [7672798.001]

[Cites] Acta Neuropathol. 1995;90(3):319-22 [8525807.001]

[Cites] J Pediatr. 1995 Nov;127(5):718-22 [7472822.001]

[Cites] Ann Neurol. 1997 Feb;41(2):143-9 [9029062.001]

[Cites] J Neurooncol. 1997 May;32(3):235-41 [9049885.001]

[Cites] J Neurosurg. 1997 May;86(5):747-54 [9126887.001]

[Cites] Cancer Genet Cytogenet. 1997 Aug;97(1):39-53 [9242217.001]

[Cites] J Clin Oncol. 1997 Aug;15(8):2792-9 [9256121.001]

[Cites] Childs Nerv Syst. 1997 Oct;13(10):550-5 [9403205.001]

[Cites] Cancer Genet Cytogenet. 1998 Jul 15;104(2):157-60 [9666811.001]

[Cites] J Neuropathol Exp Neurol. 1999 Jan;58(1):46-53 [10068313.001]

[Cites] J Neurosurg. 1999 Apr;90(2 Suppl):231-3 [10199253.001]

[Cites] Eur J Hum Genet. 1999 Apr;7(3):267-73 [10234502.001]

[Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1061-8 [10515229.001]

[Cites] Klin Padiatr. 2004 Nov-Dec;216(6):331-42 [15565548.001]

[Cites] Cancer Res. 2005 Jan 1;65(1):76-84 [15665281.001]

[Cites] Cancer Res. 2005 Jan 1;65(1):236-45 [15665300.001]

[Cites] Cancer Res. 2005 Apr 1;65(7):2755-60 [15805275.001]

[Cites] Curr Biol. 2005 Apr 26;15(8):702-13 [15854902.001]

[Cites] Cancer. 2005 Jun 15;103(12):2636-42 [15861409.001]

[Cites] J Clin Oncol. 2005 Aug 1;23(22):5198-204 [16051961.001]

[Cites] Cancer Res. 2005 Aug 15;65(16):7429-35 [16103096.001]

[Cites] Neuropathol Appl Neurobiol. 2005 Oct;31(5):556-60 [16150126.001]

[Cites] Neurology. 2005 Oct 25;65(8):1335-6 [16247081.001]

[Cites] J Neurosurg. 2005 Oct;103(4 Suppl):357-61 [16270688.001]

[Cites] J Neurooncol. 2005 Dec;75(3):301-7 [16195800.001]

[Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):759-67 [11005256.001]

[Cites] Arch Ophthalmol. 2001 Apr;119(4):516-29 [11296017.001]

[Cites] Pediatr Neurosurg. 2001 May;34(5):229-34 [11423771.001]

[Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):917-20 [11556548.001]

[Cites] Childs Nerv Syst. 2001 Sep;17(9):503-11 [11585322.001]

[Cites] J Neuropathol Exp Neurol. 2002 Oct;61(10):896-902 [12387455.001]

[Cites] Front Biosci. 2003 Jan 1;8:a1-9 [12456321.001]

[Cites] J Neurosurg. 2002 Dec;97(6):1350-5 [12507133.001]

[Cites] Cancer. 2003 Feb 15;97(4):1084-92 [12569610.001]

[Cites] Childs Nerv Syst. 2003 Apr;19(4):197-203 [12682758.001]

[Cites] Neuro Oncol. 2003 Jul;5(3):188-96 [12816725.001]

[Cites] J Clin Oncol. 2003 Aug 1;21(15):2968-73 [12885817.001]

[Cites] Eur J Cancer. 2006 Aug;42(12):1807-16 [16809032.001]

[Cites] Neuropathology. 2006 Oct;26(5):442-6 [17080723.001]

[Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58 [17086101.001]

[Cites] J Clin Oncol. 2007 Feb 20;25(6):682-9 [17308273.001]

[Cites] Neuro Oncol. 2007 Apr;9(2):161-8 [17347491.001]

[Cites] Ann Neurol. 2007 Mar;61(3):189-98 [17387725.001]

[Cites] Histol Histopathol. 2007 Aug;22(8):895-903 [17503347.001]

[Cites] Neuropediatrics. 2007 Apr;38(2):61-3 [17712732.001]

[Cites] Cancer. 2003 Sep 15;98(6):1243-52 [12973849.001]

[Cites] Am J Hum Genet. 2003 Nov;73(5):1191-8 [14566704.001]

[Cites] Br J Neurosurg. 2003 Aug;17(4):327-35 [14579898.001]

[Cites] Neurol Res. 2003 Oct;25(7):691-3 [14579783.001]

[Cites] J Clin Oncol. 2003 Dec 15;21(24):4572-8 [14673044.001]

[Cites] Neurology. 2006 Jan 10;66(1):127-30 [16401863.001]

[Cites] Cancer. 2006 Jan 15;106(2):396-402 [16353203.001]

[Cites] Pediatr Blood Cancer. 2006 Mar;46(3):377-80 [15800886.001]

[Cites] Ann Neurol. 2006 Mar;59(3):490-8 [16453317.001]

[Cites] Neoplasia. 2006 Feb;8(2):136-42 [16611406.001]

[Cites] Cancer Cell. 2006 May;9(5):341-9 [16697955.001]

[Cites] J Clin Oncol. 2006 Jun 1;24(16):2570-5 [16735710.001]

[Cites] J Neurosurg. 2006 May;104(5 Suppl):314-20 [16848088.001]

[Cites] Neuro Oncol. 2007 Oct;9(4):430-7 [17704361.001]

[Cites] Br J Ophthalmol. 2008 Jan;92(1):40-6 [17962395.001]

[Cites] Biochim Biophys Acta. 2008 Jan;1784(1):116-32 [17913600.001]

[Cites] Neurosurgery. 2003 Sep;53(3):544-53; discussion 554-5 [12943571.001]

[Cites] Cancer. 2008 Feb 15;112(4):892-9 [18098210.001]

[Cites] Cancer Res. 2008 Mar 1;68(5):1520-8 [18316617.001]

[Cites] Methods Enzymol. 2008;438:307-20 [18413257.001]

[Cites] J Clin Oncol. 2008 May 1;26(13):2139-46 [18390968.001]

[Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]

[Cites] Rev Recent Clin Trials. 2007 May;2(2):121-34 [18473997.001]

[Cites] Brain Pathol. 2008 Jul;18(3):326-37 [18371186.001]

[Cites] Pediatr Blood Cancer. 2008 Aug;51(2):245-50 [18386785.001]

[Cites] Pediatr Neurosurg. 2008;44(4):324-8 [18504420.001]

[Cites] Pediatr Neurosurg. 2008;44(4):333-6 [18552517.001]

[Cites] Oncogene. 2008 Aug 7;27(34):4745-51 [18408760.001]

[Cites] PLoS One. 2008;3(8):e3065 [18725974.001]

[Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]

[Cites] J Clin Oncol. 2012 Apr 20;30(12):1358-63 [22393086.001]

[Cites] Recent Pat Antiinfect Drug Discov. 2006 Jun;1(2):241-6 [18221149.001]

[Cites] Radiother Oncol. 2000 Mar;54(3):239-45 [10738082.001]

[Cites] Clin Neuropathol. 2000 Mar-Apr;19(2):57-62 [10749285.001]

[Cites] J Neurosurg. 2000 Apr;92(4):722-5 [10761668.001]

[Cites] Int J Hematol. 2003 Dec;78(5):383-9 [14704030.001]

[Cites] Cancer Cell. 2004 Oct;6(4):313-9 [15488754.001]

[Cites] J Neurosurg. 1985 Dec;63(6):862-6 [4056900.001]

[Cites] Neurosurgery. 1988 Nov;23(5):545-56 [3143922.001]

[Cites] Proc Natl Acad Sci U S A. 1989 Nov;86(21):8323-7 [2682646.001]

[Cites] Cancer. 1990 Jan 1;65(1):45-52 [2104571.001]

[Cites] Cell. 1990 Aug 10;62(3):599-608 [2116237.001]

[Cites] J Neurosurg. 1992 Aug;77(2):302-6 [1625019.001]

[Cites] Pediatr Neurosurg. 1992;18(4):207-17 [1472434.001]

(PMID = 19164945.001).

[ISSN] 1555-8576

[Journal-full-title] Cancer biology & therapy

[ISO-abbreviation] Cancer Biol. Ther.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-31; United States / NCI NIH HHS / CA / P30 CA021765-31; United States / NCI NIH HHS / CA / P30 CA21765

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review

[Publication-country] United States

[Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf

[Number-of-references] 97

[Other-IDs] NLM/ NIHMS161402; NLM/ PMC2810626

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pilomyxoid astrocytoma of the fourth ventricle in an adult.

Pilomyxoid astrocytomas have been identified as a variant of pilocytic astrocytoma.

This tumour corresponds to a WHO grade II neoplasm whereas pilocytic astrocytoma corresponds to WHO grade I.

Pilomyxoid astrocytomas are not limited to the hypothalamic/chiasmatic region in children.

Additional knowledge and recognition of this entity is necessary to improve treatment of pilomyxoid astrocytoma.

[MeSH-major] Astrocytoma / pathology. Cerebral Ventricle Neoplasms / pathology. Fourth Ventricle / pathology

[MeSH-minor] Adult. Age Distribution. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Cranial Nerve Diseases / etiology. Cranial Nerve Diseases / physiopathology. Humans. Hyperacusis / etiology. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Tinnitus / etiology. Treatment Outcome

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18958385.001).

[ISSN] 0942-0940

[Journal-full-title] Acta neurochirurgica

[ISO-abbreviation] Acta Neurochir (Wien)

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Austria

[Chemical-registry-number] 0 / Biomarkers, Tumor

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Operative case of isomorphic astrocytoma].

Diffuse astrocytomas are classified as WHO Grade II tumors.

Recently, a subtype presenting with better prognosis has been proposed, and it is known as "isomorphic astrocytoma."

The tumor was resected under awake surgery.

The pathological diagnosis was diffuse astrocytoma, but this tumor was considered to be the isomorphic subtype.

Some parts of the tumor showed a relatively high MIB-1 labeling index (LI) of 9.2%, and additional 50-Gy radiotherapy was performed.

Isomorphic astrocytoma is characterized by prolonged epileptic seizures, a low MIB-1 LI, and better prognosis.

In our case, since the MIB-1 LI was higher in some parts of the tumor, the appropriate therapy for WHO Grade II tumors was performed.

However, this case was considered representative of isomorphic astrocytoma.

No reports of this tumor subtype have been previously described in Japan.

Therefore, this report is the first case of isomorphic astrocytoma reported to Japanese literature.

[MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17713125.001).

[ISSN] 1881-6096

[Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo

[ISO-abbreviation] Brain Nerve

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin.

Pilocytic astrocytomas (PAs) are the most common glioma in children.

Whereas many PAs are slow-growing or clinically indolent, others exhibit more aggressive features with tumor recurrence and death.

Lastly, we also identified a gene expression pattern common to PAs and normal mouse astrocytes and neural stem cells from these distinct brain regions as well as a gene expression pattern shared between PAs and another human glial tumor (ependymoma) arising supratentorially compared with those originating in the posterior fossa.

[MeSH-major] Astrocytoma / genetics. Infratentorial Neoplasms / genetics. Supratentorial Neoplasms / genetics

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17283119.001).

[ISSN] 0008-5472

[Journal-full-title] Cancer research

[ISO-abbreviation] Cancer Res.

[Language] eng

[Databank-accession-numbers] GEO/ GSE5582/ GSE5675

[Grant] United States / NCI NIH HHS / CA / P30 CA 91842

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] No aberrant methylation of neurofibromatosis 1 gene (NF1) promoter in pilocytic astrocytoma in childhood.

With 30-40% of this heterogenous group, low-grade astrocytomas represent the most common subtype.

Neurofibromatosis type 1 (NF1) is strongly associated with the development of pilocytic astrocytoma (PA), frequently appearing as optic glioma.

Neurofibromatosis 1 gene (NF1 ) fulfills the criteria of a tumor suppressor gene and is deleted or mutated heterozygously in patients with NF1.

To rule out that silencing of NF1 by promoter methylation is restricted to higher-grade astrocytomas, 15 pediatric WHO II degree and IV degree astrocytomas were analyzed: 12 astrocytomas II and 3 glioblastomas displayed no NF1 promoter methylation.

The authors conclude that NF1 silencing by methylation plays no role in low-grade astrocytoma.

Genetic Alliance. consumer health - Neurofibromatosis.

Genetic Alliance. consumer health - Neurofibromatosis type 1.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15770836.001).

[ISSN] 0888-0018

[Journal-full-title] Pediatric hematology and oncology

[ISO-abbreviation] Pediatr Hematol Oncol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Neurofibromin 1

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Here, we report a 19-year-old Saudi girl diagnosed as a case of astrocytoma grade II arising from the right thalamus.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 22473142.001).

[ISSN] 1319-6138

[Journal-full-title] Neurosciences (Riyadh, Saudi Arabia)

[ISO-abbreviation] Neurosciences (Riyadh)

[Language] eng

[Publication-type] Journal Article

[Publication-country] Saudi Arabia

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

As a rule, their behaviour can be predicted from histology: Grade I (pilocytic astrocytomas) and Grade II (benign astrocytomas) tumours are of low grade and grow slowly over many years.

Grade IV tumours (GBM) are the most aggressive and, unfortunately, also the most common in humans, growing rapidly, invading and altering brain function.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Res. 1995 Nov 1;55(21):4833-6 [7585516.001]

[Cites] Cancer. 1980 Jan 1;45(1):112-25 [6985826.001]

[Cites] J Neurosurg. 1970 Jul;33(1):88-94 [4316740.001]

[Cites] Cancer. 1992 Apr 15;69(8):2149-53 [1311985.001]

[Cites] J Neurosurg. 2000 Nov;93(5):887-90 [11059674.001]

[Cites] Clin Imaging. 1994 Oct-Dec;18(4):386-9 [8000959.001]

(PMID = 21614314.001).

[ISSN] 1823-5530

[Journal-full-title] Biomedical imaging and intervention journal

[ISO-abbreviation] Biomed Imaging Interv J

[Language] eng

[Publication-type] Journal Article

[Publication-country] Malaysia

[Other-IDs] NLM/ PMC3097703

[Keywords] NOTNLM ; GBM / Glioblastoma multiforme / extracranial metastases / glioma

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVE: To investigate the demographic, clinical, radiological, pathological and surgical features and outcomes of infantile intracranial neoplasms, the second most common neoplasm in infants.

The most common tumor was choroid plexus papilloma (23.8%), followed by teratoma (19%) then astrocytoma and ependymoma (14.3% each).

The statistically significant predictors of prognosis were the extent of resection and tumor grade.

[MeSH-minor] Adolescent. Astrocytoma / drug therapy. Astrocytoma / mortality. Astrocytoma / surgery. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Egypt / epidemiology. Ependymoma / drug therapy. Ependymoma / mortality. Ependymoma / surgery. Female. Humans. Infant. Infant, Newborn. Male. Medulloblastoma / drug therapy. Medulloblastoma / mortality. Medulloblastoma / surgery. Morbidity. Neurilemmoma / drug therapy. Neurilemmoma / mortality. Neurilemmoma / surgery. Prognosis. Quality of Life. Referral and Consultation / statistics & numerical data. Retrospective Studies. Teratoma / drug therapy. Teratoma / mortality. Teratoma / surgery

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2010 S. Karger AG, Basel.

(PMID = 21160236.001).

[ISSN] 1423-0305

[Journal-full-title] Pediatric neurosurgery

[ISO-abbreviation] Pediatr Neurosurg

[Language] eng

[Publication-type] Journal Article

[Publication-country] Switzerland

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Infiltrating growing pattern xenografts induced by glioblastoma and anaplastic astrocytoma derived tumor stem cells.

OBJECTIVE: The number of evidences regarding the role of tumor stem cells (TSC) in the initiation and progression of high-grade astrocytomas became more and more numerous in the last years.

This issue has been intensively tested in glioblastoma, but little attention has been paid for anaplastic astrocytoma.

The main objective of this paper was to study the morphological characteristics of the xenografts developed from glioblastoma and anaplastic astrocytoma derived cancer stem cells.

METHODS: The authors of this study successfully isolated and partial characterized primary cultures of glioblastoma and anaplastic astrocytoma derived TSC.

RESULTS: The tumor xenografts which have been established in nude mice using TSC had different characteristics when compared with U87 xenografts previously developed by our group, and depend of the origin type of the tumors (glioblastoma versus anaplastic astrocytoma).

The diffuse growing pattern and cells infiltration have been more pronounced in both anaplastic astrocytoma and glioblastoma derived TSC xenografts compared with U87 line xenografts.

CONCLUSION: Our results support the hypothesis regarding the role of TSC in the infiltration process of glioblastoma and anaplastic astrocytoma.

[MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology. Neoplastic Stem Cells / pathology. Transplantation, Heterologous

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21141095.001).

[ISSN] 1221-9118

[Journal-full-title] Chirurgia (Bucharest, Romania : 1990)

[ISO-abbreviation] Chirurgia (Bucur)

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Romania

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.

WHO grading of human brain tumors extends beyond a strictly histological grading system by providing a basis predictive for the clinical behavior of the respective neoplasm.

For example, patients with glioblastoma WHO grade IV usually show a less favorable clinical course and receive more aggressive first-line treatment than patients with anaplastic astrocytoma WHO grade III.

Here we provide evidence that the IDH1 status is more prognostic for overall survival than standard histological criteria that differentiate high-grade astrocytomas.

We sequenced the isocitrate dehydrogenase 1 gene (IDH1) at codon 132 in 382 patients with anaplastic astrocytoma and glioblastoma from the NOA-04 trial and from a prospective translational cohort study of the German Glioma Network.

Patients with anaplastic astrocytomas carried IDH1 mutations in 60%, and patients with glioblastomas in 7.2%.

The sequence from more favorable to poorer outcome was (1) anaplastic astrocytoma with IDH1 mutation, (2) glioblastoma with IDH1 mutation, (3) anaplastic astrocytoma without IDH1 mutation and (4) glioblastoma without IDH1 mutation (p < 0.0001).

In this combined set of anaplastic astrocytomas and glioblastomas both, IDH1 mutation and IDH1 expression status were of greater prognostic relevance than histological diagnosis according to the current WHO classification system.

We propose to complement the current WHO classification and grading of high-grade astrocytic gliomas by the IDH1 mutation status and to use this combined histological and molecular classification in future clinical trials.

[MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Astrocytoma / diagnosis. Astrocytoma / genetics. Astrocytoma / pathology. Cohort Studies. Female. Humans. Male. Middle Aged. Prognosis. Prospective Studies. Young Adult

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21088844.001).

[ISSN] 1432-0533

[Journal-full-title] Acta neuropathologica

[ISO-abbreviation] Acta Neuropathol.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Astrocytoma was the most frequently diagnosed pathology in both eras accounting for nearly 90% of biopsies.

Mortality, on follow-up, in children with diffuse low- and high-grade astrocytoma was similar.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2010 S. Karger AG, Basel.

(PMID = 20861659.001).

[ISSN] 1423-0372

[Journal-full-title] Stereotactic and functional neurosurgery

[ISO-abbreviation] Stereotact Funct Neurosurg

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] Switzerland

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702).

The purpose of this study was to identify risk factors for the progression of low-grade glioma in children from a large population-based cohort.

Patient and tumor details of a national cohort of children with low-grade glioma, recruited into an international multidisciplinary clinical strategy, were subjected to univariate and multivariate analyses of progression-free survival and overall survival.

From the cohort of 798 patients, 639 patients were eligible, with a median age 6.71 years (0.26-16.75 years); 49% were males; 15.9% had neurofibromatosis type 1, 63.7% pilocytic astrocytoma, 5.9% fibrillary astrocytoma, 4.2% mixed neuronal-glial tumors, and 3.6% others; 21.1% were diagnosed clinically.

There was a significant association between age and site (P < .001) and extent of tumor resection and site (P < .001).

Multivariate analysis identified young age, fibrillary astrocytoma, and extent of surgical resection as significant independent risk factors for progression.

In conclusion, the influence of age and anatomical site upon the risk of tumor progression suggests that these factors strongly influence tumor behavior for the majority of pilocytic tumors.

Genetic Alliance. consumer health - Glioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Childs Nerv Syst. 2005 Nov;21(11):940-4 [16044344.001]

[Cites] Brain Pathol. 2009 Jul;19(3):449-58 [19016743.001]

[Cites] Eur J Cancer. 2006 Aug;42(12):1807-16 [16809032.001]

[Cites] Cancer Res. 2007 Feb 1;67(3):890-900 [17283119.001]

[Cites] J Pediatr Hematol Oncol. 2007 Jul;29(7):465-70 [17609624.001]

[Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]

[Cites] Cancer Res. 2007 Sep 15;67(18):8588-95 [17875698.001]

[Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]

[Cites] Pediatr Blood Cancer. 2008 Aug;51(2):245-50 [18386785.001]

[Cites] Pediatr Neurosurg. 2008;44(4):324-8 [18504420.001]

[Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]

[Cites] Br J Radiol. 2008 Oct;81(970):761-6 [18796556.001]

[Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]

[Cites] J Pathol. 2009 Jun;218(2):172-81 [19373855.001]

[Cites] Oncogene. 2009 May 21;28(20):2119-23 [19363522.001]

[Cites] BMJ. 2001 Jul 28;323(7306):224-8 [11473921.001]

[Cites] Childs Nerv Syst. 2001 Sep;17(9):503-11 [11585322.001]

[Cites] Cancer. 2001 Dec 15;92(12):3155-64 [11753995.001]

[Cites] J Clin Oncol. 2002 Jul 1;20(13):2951-8 [12089224.001]

[Cites] J Clin Oncol. 2002 Oct 15;20(20):4209-16 [12377964.001]

[Cites] Cancer. 2003 Feb 15;97(4):1084-92 [12569610.001]

[Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):807-12 [12788189.001]

[Cites] Cancer. 2003 Sep 15;98(6):1243-52 [12973849.001]

[Cites] J Clin Oncol. 2003 Dec 15;21(24):4572-8 [14673044.001]

[Cites] J Neurosurg. 1984 Oct;61(4):665-73 [6470776.001]

[Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):215-25 [8420869.001]

[Cites] JAMA. 1994 Jul 20;272(3):234-7 [8022043.001]

[Cites] Med Pediatr Oncol. 1995 Feb;24(2):104-8 [7990757.001]

[Cites] J Neurosurg. 1995 Apr;82(4):536-47 [7897512.001]

[Cites] J Neurosurg. 1997 May;86(5):747-54 [9126887.001]

[Cites] J Clin Oncol. 1997 Aug;15(8):2792-9 [9256121.001]

[Cites] J Clin Oncol. 1997 Sep;15(9):3129-40 [9294476.001]

[Cites] Pediatr Neurosurg. 1998 Jul;29(1):23-8 [9755308.001]

[Cites] Childs Nerv Syst. 1998 Nov;14(11):636-48 [9840364.001]

[Cites] J Child Neurol. 1999 Jun;14(6):352-6 [10385841.001]

[Cites] Am J Med Genet. 1999 Mar 26;89(1):38-44 [10469435.001]

[Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1061-8 [10515229.001]

[Cites] Klin Padiatr. 2004 Nov-Dec;216(6):331-42 [15565548.001]

[Cites] Nat Rev Cancer. 2005 Jun;5(6):481-8 [15905853.001]

[Cites] Cancer. 2006 Mar 15;106(6):1358-63 [16470608.001]

(PMID = 20861086.001).

[ISSN] 1523-5866

[Journal-full-title] Neuro-oncology

[ISO-abbreviation] Neuro-oncology

[Language] eng

[Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Other-IDs] NLM/ PMC3018938

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: Previous researches have indicated that glioma invasion may occur within a tumor-host microecology, and that fibronectin may be involved in glioma invasion as an important component of the extracellular matrix.

However, how the interaction between tumor cells and vascular endothelial cells affects glioma invasion is poorly understood.

The aim of this study was to investigate the effects of the interaction between tumor cells and vascular endothelial cells on glioma invasion, and the relationship of this interaction to fibronectin.

METHODS: The localization of fibronectin in different brain astrocytoma tissues was determined by immunohistochemistry.

Additionally, the influence of the interaction between tumor cells and vascular endothelial cells on glioma cell invasion was determined by an in vitro rapid invasion test.

RESULTS: In brain astrocytoma tissues, fibronectin was present on the endothelial cells, in the extracellular matrix.

Fibronectin expression was greater in higher grade tumors than in lower grade tumors.

[MeSH-minor] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Cell Movement / physiology. Cells, Cultured. Coculture Techniques. Enzyme-Linked Immunosorbent Assay. Humans. Immunohistochemistry. Reverse Transcriptase Polymerase Chain Reaction

Genetic Alliance. consumer health - Glioma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20819642.001).

[ISSN] 0366-6999

[Journal-full-title] Chinese medical journal

[ISO-abbreviation] Chin. Med. J.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / Fibronectins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma.

Malignant astrocytoma includes anaplastic astrocytoma (grade III) and glioblastoma (grade IV).

Among them, glioblastoma is the most common primary brain tumor with dismal responses to all therapeutic modalities.

We performed a large-scale, genome-wide microRNA (miRNA) (n=756) expression profiling of 26 glioblastoma, 13 anaplastic astrocytoma and 7 normal brain samples with an aim to find deregulated miRNA in malignant astrocytoma.

More importantly, we identified a most discriminatory 23-miRNA expression signature, by using PAM, which precisely distinguished glioblastoma from anaplastic astrocytoma with an accuracy of 95%.

The differential expression pattern of nine miRNAs was further validated by real-time RT-PCR on an independent set of malignant astrocytomas (n=72) and normal samples (n=7).

Thus we have identified the miRNA expression signature for malignant astrocytoma, in particular glioblastoma, and showed the miRNA involvement and their importance in astrocytoma development.

[MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. MicroRNAs / genetics

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20711171.001).

[ISSN] 1530-0285

[Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

[ISO-abbreviation] Mod. Pathol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

MATERIALS AND METHODS: Nine baseline and 24 follow-up DTI studies performed in 9 patients on a 1.5T clinical MR imaging scanner were reviewed.

Reference data were obtained from 8 controls with normal brain stem, 6 patients with medulloblastoma, and 7 patients with pilocytic astrocytoma.

FA was lower in DIBSG than in normal brain stem (0.24 ± 0.04 versus 0.43 ± 0.02, P < .001) but was higher than that in pilocytic astrocytoma (0.17 ± 0.05, P < .05).

[MeSH-major] Astrocytoma / pathology. Brain Stem Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods. Medulloblastoma / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20595371.001).

[ISSN] 1936-959X

[Journal-full-title] AJNR. American journal of neuroradiology

[ISO-abbreviation] AJNR Am J Neuroradiol

[Language] eng

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Transliterated title] Etude de sept cas de méningiomes à cellules claires et revue de la littérature.

CONCLUSION: Our study supports the fact that MCC course is less favourable than meningioma WHO grade I, even in the absence of anaplastic area, high mitotic activity, or necrosis.

[MeSH-major] Biomarkers, Tumor / analysis. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Proteins / analysis

[MeSH-minor] Adult. Aged. Astrocytoma / diagnosis. Child, Preschool. Diagnostic Errors. Ependymoma / diagnosis. Female. Humans. Keratins / analysis. Ki-67 Antigen / analysis. Male. Middle Aged. Mucin-1 / analysis. Neurofibromatosis 2 / diagnosis. Neurofibromatosis 2 / genetics. Neurofibromatosis 2 / pathology. Receptors, Progesterone / analysis. Retrospective Studies. S100 Proteins / analysis. Young Adult

Genetic Alliance. consumer health - Meningioma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.

(PMID = 20451062.001).

[ISSN] 0242-6498

[Journal-full-title] Annales de pathologie

[ISO-abbreviation] Ann Pathol

[Language] fre

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] France

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Mucin-1; 0 / Neoplasm Proteins; 0 / Receptors, Progesterone; 0 / S100 Proteins; 68238-35-7 / Keratins

[Number-of-references] 33

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Medulloblastoma, ependymoma, supratentorial primitive neuroectodermal tumors, and pilocytic astrocytoma are the most prevalent types, all of which are clinically, histologically, and genetically heterogeneous.

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Neuropediatrics. 2007 Apr;38(2):61-3 [17712732.001]

[Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]

[Cites] Trends Mol Med. 2005 Jan;11(1):17-22 [15649818.001]

[Cites] Clin Cancer Res. 2004 Nov 15;10(22):7613-20 [15569993.001]

[Cites] Hum Pathol. 2005 Jan;36(1):36-43 [15712180.001]

[Cites] J Clin Oncol. 2006 Nov 20;24(33):5223-33 [17114655.001]

[Cites] Genes Chromosomes Cancer. 2007 Sep;46(9):839-51 [17592618.001]

[Cites] Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R96-105 [17613554.001]

[Cites] Cancer Res. 2007 Feb 1;67(3):890-900 [17283119.001]

[Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58 [17086101.001]

[Cites] Cancer. 1999 Jul 15;86(2):331-9 [10421270.001]

[Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2070-9 [16609018.001]

[Cites] Clin Cancer Res. 2005 Jul 1;11(13):4733-40 [16000568.001]

[Cites] Histopathology. 2006 Apr;48(5):579-87 [16623784.001]

[Cites] Brain Pathol. 2009 Jul;19(3):449-58 [19016743.001]

[Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]

[Cites] Oncogene. 2009 May 21;28(20):2119-23 [19363522.001]

[Cites] Childs Nerv Syst. 2009 Oct;25(10):1195-201 [19536551.001]

[Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]

[Cites] Nat Genet. 2008 Jun;40(6):741-50 [18488029.001]

[Cites] J Clin Oncol. 2006 Apr 20;24(12):1924-31 [16567768.001]

[Cites] Br J Cancer. 2009 Aug 18;101(4):722-33 [19603027.001]

[Cites] Neurosurg Focus. 2005 Nov 15;19(5):E10 [16398460.001]

[Cites] Neurosurgery. 2000 Oct;47(4):888-901 [11014429.001]

[Cites] Neuropathol Appl Neurobiol. 2002 Aug;28(4):325-33 [12175345.001]

[Cites] J Clin Oncol. 2009 Apr 10;27(11):1884-92 [19289631.001]

[Cites] Cell Cycle. 2006 Nov;5(22):2666-70 [17172831.001]

[Cites] Neuro Oncol. 2008 Dec;10(6):981-94 [18664619.001]

[Cites] Acta Neuropathol. 2009 Sep;118(3):401-5 [19543740.001]

[Cites] Oncogene. 2006 Feb 16;25(7):1111-7 [16186793.001]

[Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):549-61 [16783165.001]

[Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]

[Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]

[Cites] Br J Cancer. 2000 Mar;82(6):1218-22 [10735509.001]

[Cites] J Pathol. 2009 Jun;218(2):172-81 [19373855.001]

[Cites] Recent Results Cancer Res. 2009;171:67-81 [19322538.001]

[Cites] Nat Genet. 2009 Apr;41(4):465-72 [19270706.001]

[Cites] Lancet Neurol. 2007 Dec;6(12):1073-85 [18031705.001]

[Cites] Annu Rev Pathol. 2008;3:341-65 [18039127.001]

[Cites] Histopathology. 2005 Dec;47(6):631-7 [16324202.001]

[Cites] Lancet Oncol. 2006 Oct;7(10):813-20 [17012043.001]

[Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2812-7 [19196975.001]

[Cites] Nature. 2002 Jan 24;415(6870):436-42 [11807556.001]

[Cites] J Clin Oncol. 2009 Apr 1;27(10 ):1627-36 [19255330.001]

[Cites] Cancer Res. 2008 Dec 1;68(23):9945-53 [19047176.001]

[Cites] Nucleic Acids Res. 2007;35(7):e51 [17344319.001]

[Cites] PLoS One. 2008 Aug 28;3(8):e3088 [18769486.001]

[Cites] Nature. 1990 Dec 20-27;348(6303):747-9 [2259385.001]

[Cites] Neurology. 2005 Oct 25;65(8):1335-6 [16247081.001]

[Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]

[Cites] Cancer Res. 2009 Apr 15;69(8):3249-55 [19351822.001]

[Cites] Cancer. 2000 May 1;88(9):2189-93 [10813733.001]

[Cites] Ann Neurol. 2007 Mar;61(3):189-98 [17387725.001]

[Cites] J Biol Chem. 2003 Jul 18;278(29):26958-69 [12730209.001]

[Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]

(PMID = 20425037.001).

[ISSN] 1534-6293

[Journal-full-title] Current neurology and neuroscience reports

[ISO-abbreviation] Curr Neurol Neurosci Rep

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 55

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomas.

To identify glioma-associated genes, we evaluated tumor formation in the brain tissue from 117 transgenic mice that had undergone constitutive SB-mediated transposition.

Upon analysis, 21 samples (18%) contained neoplastic tissue with features of high-grade astrocytomas.

Genomic DNA from SB-induced astrocytoma tissue was extracted and transposon insertion sites were identified.

Using reverse transcription-PCR, we documented increased Csf1 RNAs in tumor versus adjacent normal tissue, with the identification of transposon-terminated Csf1 mRNAs in astrocytomas with SB insertions in intron 8.

Together, these results indicate that SB-insertional mutagenesis can identify high-grade astrocytoma-associated genes and they imply an important role for CSF1 in the development of these tumors.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c)2010 AACR.

[Cites] Nat Genet. 2000 Dec;26(4):424-9 [11101838.001]

[Cites] Cancer Res. 2007 Mar 1;67(5):1918-26 [17332318.001]

[Cites] Int Immunopharmacol. 2008 Oct;8(10):1354-76 [18687298.001]

[Cites] J Pathol. 2008 Sep;216(1):15-24 [18553315.001]

[Cites] Mol Cancer Res. 2008 Aug;6(8):1375-84 [18708368.001]

[Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]

[Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]

[Cites] Cancer Res. 2008 Nov 15;68(22):9125-30 [19010882.001]

[Cites] Nat Biotechnol. 2009 Mar;27(3):264-74 [19234449.001]

[Cites] Science. 2009 Mar 27;323(5922):1747-50 [19251594.001]

[Cites] Cancer Res. 2009 May 15;69(10):4388-97 [19401450.001]

[Cites] Nat Genet. 2009 Aug;41(8):905-8 [19578366.001]

[Cites] Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12530-5 [19617536.001]

[Cites] Cancer Res. 2009 Nov 1;69(21):8429-37 [19843846.001]

[Cites] Neuro Oncol. 2009 Dec;11(6):803-18 [19304958.001]

[Cites] Oncogene. 2000 Dec 7;19(52):5964-72 [11146547.001]

[Cites] Oncogene. 2000 Dec 18;19(55):6482-9 [11175364.001]

[Cites] J Exp Med. 2001 Mar 19;193(6):727-40 [11257139.001]

[Cites] Genesis. 2001 Jun;30(2):82-8 [11416868.001]

[Cites] Neuroscience. 2002;112(4):889-900 [12088748.001]

[Cites] Nat Genet. 2002 Sep;32(1):153-9 [12185366.001]

[Cites] Science. 2003 Jun 13;300(5626):1749-51 [12805549.001]

[Cites] Genetics. 2003 Sep;165(1):243-56 [14504232.001]

[Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D523-7 [14681473.001]

[Cites] Acta Neuropathol. 2004 Mar;107(3):277-82 [14730454.001]

[Cites] Br J Haematol. 1971 Oct;21(4):481-92 [5122671.001]

[Cites] Cancer. 1991 Feb 15;67(4):990-6 [1825026.001]

[Cites] J Neurosurg. 1994 Jun;80(6):1063-73 [7514661.001]

[Cites] Blood. 1996 Jun 15;87(12):5232-41 [8652838.001]

[Cites] Mol Reprod Dev. 1997 Jan;46(1):4-10 [8981357.001]

[Cites] EMBO J. 1998 Sep 1;17(17):4964-74 [9724633.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10769-73 [9724779.001]

[Cites] Cancer Res. 1999 May 1;59(9):2217-22 [10232611.001]

[Cites] Trends Genet. 1999 Aug;15(8):326-32 [10431195.001]

[Cites] Yeast. 1999 Aug;15(11):1097-109 [10455233.001]

[Cites] PLoS Biol. 2004 Nov;2(11):e363 [15502875.001]

[Cites] Nature. 2005 Jul 14;436(7048):221-6 [16015321.001]

[Cites] Nature. 2005 Jul 14;436(7048):272-6 [16015333.001]

[Cites] Cancer Res. 2005 Nov 1;65(21):9607-10 [16266976.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):690-5 [16407111.001]

[Cites] Clin Cancer Res. 2006 Sep 15;12(18):5288-97 [17000661.001]

[Cites] Biochem Biophys Res Commun. 2007 Feb 23;353(4):902-7 [17196930.001]

[Cites] Stem Cells. 2007 Feb;25(2):371-9 [17038675.001]

[Cites] BMC Neurosci. 2007;8:28 [17474996.001]

(PMID = 20388773.001).

[ISSN] 1538-7445

[Journal-full-title] Cancer research

[ISO-abbreviation] Cancer Res.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA113636-02; United States / NCI NIH HHS / CA / CA113636-03; United States / NCI NIH HHS / CA / R01CA113636; United States / NCI NIH HHS / CA / R01 CA113636-03; United States / NCI NIH HHS / CA / K01CA122183; United States / NCI NIH HHS / CA / T32 CA009138; United States / NCI NIH HHS / CA / R01 CA113636-05; United States / NCI NIH HHS / CA / R01 CA113636-01A1; United States / NCI NIH HHS / CA / CA113636-01A1; United States / NCI NIH HHS / CA / R01 CA113636; United States / NCI NIH HHS / CA / CA113636-05; United States / NCI NIH HHS / CA / R01 CA113636-04; United States / NCI NIH HHS / CA / CA113636-02; United States / NCI NIH HHS / CA / K01 CA122183; United States / NCI NIH HHS / CA / CA113636-04

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / DNA Transposable Elements; 0 / RNA, Messenger; 81627-83-0 / Macrophage Colony-Stimulating Factor; EC 2.7.10.1 / Receptor, Macrophage Colony-Stimulating Factor; EC 2.7.7.- / Transposases

[Other-IDs] NLM/ NIHMS185042; NLM/ PMC2862088

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Natural history and management of low-grade glioma in NF-1 children.

Pediatric neurofibromatosis type 1 (NF-1) patients are prone to developing low-grade glioma (LGG).

Eighty-three patients (76%) suffered from an optic pathway tumor.

Histology revealed pilocytic astrocytoma WHO grade I in 38 of 42 biopsied patients.

Multivariate analysis revealed surgical intervention and localization within the optic pathway as factors that increased the risk of tumor progression.

Genetic Alliance. consumer health - Glioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Med Genet. 1999 Mar 26;89(1):38-44 [10469435.001]

[Cites] Neurology. 2004 Nov 23;63(10):1944-6 [15557519.001]

[Cites] J Neurosurg. 1997 May;86(5):747-54 [9126887.001]

[Cites] J Neurosurg. 1993 Jul;79(1):32-5 [8315466.001]

[Cites] Klin Padiatr. 2004 Nov-Dec;216(6):331-42 [15565548.001]

[Cites] Br J Cancer. 2006 Jul 17;95(2):233-8 [16786042.001]

[Cites] Childs Nerv Syst. 2000 Jul;16(7):417-20 [10958550.001]

[Cites] Klin Padiatr. 2000 Jul-Aug;212(4):177-84 [10994547.001]

[Cites] Br J Radiol. 2001 Jan;74(877):24-31 [11227773.001]

[Cites] J Child Neurol. 2002 Aug;17(8):630-7; discussion 646-51 [12403562.001]

[Cites] Cancer Res. 2007 Sep 15;67(18):8588-95 [17875698.001]

[Cites] Arch Dis Child. 1998 May;78(5):408-12 [9659085.001]

[Cites] Ann Neurol. 1999 Mar;45(3):393-6 [10072056.001]

[Cites] Neurology. 2005 Feb 8;64(3):553-5 [15699396.001]

[Cites] Childs Nerv Syst. 2002 Feb;18(1-2):43-7 [11935243.001]

[Cites] J Clin Oncol. 2002 Oct 15;20(20):4209-16 [12377964.001]

[Cites] Neurology. 2006 Oct 24;67(8):1509-12 [17060590.001]

[Cites] Brain. 2003 Jan;126(Pt 1):152-60 [12477702.001]

[Cites] Curr Opin Neurol. 2004 Apr;17(2):101-5 [15021234.001]

[Cites] Oncologist. 2000;5(6):477-85 [11110599.001]

[Cites] Eur J Cancer. 2006 Aug;42(12):1807-16 [16809032.001]

[Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):917-20 [11556548.001]

[Cites] J Clin Oncol. 2003 Dec 15;21(24):4572-8 [14673044.001]

[Cites] J Clin Oncol. 2006 Jun 1;24(16):2570-5 [16735710.001]

[Cites] AMA Arch Neurol Psychiatry. 1958 Jun;79(6):607-21 [13532071.001]

[Cites] Genet Epidemiol. 2001 Jan;20(1):75-86 [11119298.001]

[Cites] Cancer. 1995 Feb 15;75(4):1051-9 [7842408.001]

[Cites] Med Pediatr Oncol. 1995 Feb;24(2):104-8 [7990757.001]

[Cites] Pediatr Neurosurg. 2000 Mar;32(3):154-62 [10867564.001]

[Cites] Childs Nerv Syst. 2006 Oct;22(10):1332-7 [16639629.001]

[Cites] Ann Neurol. 2007 Mar;61(3):189-98 [17387725.001]

[Cites] Neurology. 2003 Nov 25;61(10):1397-400 [14638962.001]

[Cites] J Neurosurg. 1995 Mar;82(3):418-29 [7861220.001]

(PMID = 20352473.001).

[ISSN] 1573-7373

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Using 36 biopsies from patients with brain tumors [12 glioblastoma multiforme (GBM); 10 low-grade (LG), including 7 schwannoma and 3 pylocytic astrocytoma; 7 meningioma (MN); 7 brain metastases (MT), including 3 adenocarcinoma and 4 breast cancer] and 9 control biopsies from patients undergoing surgery for epilepsy, we tested the hypothesis that the presence of glycine may distinguish among these brain tumor types.

Quantitative analysis revealed higher levels of Gly in tumor biopsies (all combined) relative to controls; Gly levels were significantly elevated in LG, MT and GBM biopsies (P<or=0.05).

We conclude from these findings that Gly can serve as a biomarker for brain tumors and that the Gly:Myo ratio may be a useful index for brain tumor classification.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11528-33 [11016963.001]

[Cites] Radiology. 2008 Sep;248(3):1028-35 [18710991.001]

[Cites] Nat Med. 2000 Nov;6(11):1287-9 [11062544.001]

[Cites] Radiology. 2001 May;219(2):316-33 [11323453.001]

[Cites] Eur Radiol. 2001;11(9):1784-91 [11511902.001]

[Cites] Eur Radiol. 2002 Apr;12(4):858-61 [11960238.001]

[Cites] Pediatr Res. 2002 Aug;52(2):292-300 [12149509.001]

[Cites] J Neurochem. 2002 Aug;82(4):736-54 [12358779.001]

[Cites] Magn Reson Med. 2003 Jan;49(1):29-36 [12509817.001]

[Cites] J Neurosurg. 2003 Feb;98(2):269-76 [12593610.001]

[Cites] Eur Radiol. 2003 Mar;13(3):582-91 [12594562.001]

[Cites] Biol Psychiatry. 2004 Jan 15;55(2):165-71 [14732596.001]

[Cites] Biol Psychiatry. 1988 Jan 15;23(2):210-1 [3334889.001]

[Cites] Magn Reson Med. 1992 Mar;24(1):123-36 [1556919.001]

[Cites] Neurosurgery. 1994 Oct;35(4):606-13; discussion 613-4 [7808603.001]

[Cites] MAGMA. 1996 Jun;4(2):139-50 [8875400.001]

[Cites] Br J Psychiatry. 1996 Nov;169(5):610-7 [8932891.001]

[Cites] NMR Biomed. 1997 Jan;10(1):2-12 [9251109.001]

[Cites] Biochem Biophys Res Commun. 1998 Oct 9;251(1):277-82 [9790946.001]

[Cites] AJNR Am J Neuroradiol. 2004 Nov-Dec;25(10):1696-704 [15569733.001]

[Cites] NMR Biomed. 2005 Oct;18(6):371-82 [15959923.001]

[Cites] Biochem Soc Trans. 2006 Feb;34(Pt 1):55-8 [16417482.001]

[Cites] Magn Reson Med. 2006 Mar;55(3):681-6 [16453318.001]

[Cites] NMR Biomed. 2006 Apr;19(2):223-30 [16485320.001]

[Cites] NMR Biomed. 2006 Apr;19(2):255-63 [16541464.001]

[Cites] Magn Reson Med. 2006 Jun;55(6):1257-64 [16685733.001]

[Cites] Int J Mol Med. 2007 Aug;20(2):199-208 [17611638.001]

[Cites] Neoplasia. 2007 Nov;9(11):882-92 [18030356.001]

[Cites] NMR Biomed. 2008 Mar;21(3):233-41 [17562554.001]

[Cites] Magn Reson Med. 2008 Sep;60(3):727-31 [18727088.001]

[Cites] Magn Reson Med. 2008 Oct;60(4):782-9 [18816828.001]

[Cites] MAGMA. 2009 Feb;22(1):33-41 [18830648.001]

[Cites] MAGMA. 2009 Feb;22(1):1-4 [18949497.001]

[Cites] AJNR Am J Neuroradiol. 2000 Oct;21(9):1645-9 [11039343.001]

(PMID = 20043062.001).

[ISSN] 1791-2423

[Journal-full-title] International journal of oncology

[ISO-abbreviation] Int. J. Oncol.

[Language] ENG

[Grant] United States / NIGMS NIH HHS / GM / P50 GM021700; United States / NIGMS NIH HHS / GM / P50GM021700

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] Greece

[Chemical-registry-number] 0 / Biomarkers, Tumor; 4L6452S749 / Inositol; TE7660XO1C / Glycine

[Other-IDs] NLM/ PMC3715372